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ABSTRACT 
Robin R. Craven: The Interaction of Francisella tularensis with Lung Epithelial Cells 
(Under the direction of Thomas H. Kawula) 
Francisella tularensis, a gram-negative facultative intracellular bacterial pathogen, is 
the causative agent of the disease tularemia in humans and other mammalian hosts. While 
tularemia can be acquired by a number of routes, the respiratory route results in the most 
severe disease. As few as 10 organisms can lead to pneumonic tularemia, which can have a 
fatality rate as high as 30-60% if untreated.  
Macrophages have long been considered the primary site of F. tularensis replication 
in infected animals, and many of the genes identified as necessary for virulence are related to 
survival and replication in the macrophage. However, we demonstrate that F. tularensis also 
invades and replicates within type II alveolar epithelial (ATII) cells in a mouse model of  
respiratory tularemia. We used TC-1 cells, a mouse lung epithelial cell line, to study F. 
tularensis invasion and intracellular trafficking within nonphagocytic cells. Live and killed 
F. tularensis live vaccine strain (LVS) associated with, and was internalized by, TC-1 cells 
with a similar frequency and kinetics. Inhibitors of microfilament and microtubule activity 
resulted in significantly decreased F. tularensis invasion, as did inhibitors of PI3 kinase and 
tyrosine kinase activity. Once internalized, F. tularensis containing endosomes associated 
with EEA1 then LAMP-1, followed by bacterial escape into the cytoplasm. Collectively 
these results suggest that F. tularensis epithelial cell invasion is mediated by a preformed 
ligand on the bacterial surface and driven by host cell processes, and that internalized F. 
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tularensis trafficks along the endocytic pathway before escape into the epithelial cell 
cytoplasm where replication takes place. 
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CHAPTER 1 
Introduction 
History 
The initial descriptions of the disease tularemia and the bacterium that causes it 
emerged almost simultaneously from several American labs during 1911-1914 (102). The   
U. S. Public Health Service established a lab in California in response to plague cases 
occurring after the San Francisco earthquake of 1906. Thousands of rodents from the region 
were cultured for the presence of the plague-causing bacteria, then known as Bacillus pestis. 
Observant researchers recognized that some ground squirrels tested had an infection that was 
indistinguishable from plague, except that they were unable to culture Bacillus pestis from 
these animals. In 1911 George McCoy published these findings in an article entitled “A 
Plague-Like Disease of Rodents” (71). McCoy reported that the disease could be transmitted 
to a variety of healthy animals, and could be experimentally transmitted by fleas. While 
researchers were unable to grow the causative agent, they did observe small bacilli in some 
samples. McCoy went on to point out in this paper that the number of species susceptible to 
this disease lead to suspicion that man might be susceptible as well. In 1912 McCoy and 
C.W. Chapin announced that they had cultured the organism causing the plague-like disease, 
and given it the name Bacterium tularense (72).  
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During the same time period that McCoy and Chapin were studying rodents in 
California, a physician in Utah noticed a sickness in his patients that was associated with 
biting flies (102). Dr. R. A. Pearse presented a paper titled “Insect Bites” to the Sixteenth 
Annual Meeting of the Utah State Medical Association in 1910 (78). The paper, describing 
an ulcer at the site of a fly bite, followed by swollen and suppurated lymph nodes in the 
region of the bite, fever and chills was published in March, 1911, one month before McCoy’s 
description of the disease in squirrels. Pearse described cases in 6 patients, with severity 
ranging from mild to deadly (78).  
In 1914 Wheery and Lamb described a case of a 21 year old meat cutter in Cincinnati, 
Ohio, who was treated for an ulcerative conjunctivitis (115). Though initial cultures of the 
lesions were negative, a guinea pig injected with material from the ulcer died six days later of 
a disease resembling the plague-like disease of rodents described by McCoy. Wheery and 
Lamb were able to grow Bacterium tularense using the egg-yolk culture medium described 
by McCoy and Chapin, hence identifying the first confirmed human case of the disease that 
would come to be known as tularemia (102). 
Numerous incidents of a disease resembling tularemia were described in the Soviet 
Union in the 1920s (82), most frequently associated with contact with water rats. This disease 
could be propagated in animals following injection of the lymph node contents of infected 
people, and the causative agent of the animal infections could be cultured using egg yolk 
medium. However, definitive identification of the Russian illness as tularemia would not 
occur until 1929-1930, when the serum of G.I. Zarkhi, a researcher who had contracted the 
illness, was sent to McCoy for testing.  The serum agglutinated the American B. tularense 
culture, and bacteria cultured from infected Russian lab animals had the same characteristics 
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as the American strain, confirming the presence of tularemia in Europe (82). Once tularemia 
had been identified and described, many illnesses in North America, Europe and Japan that 
had previously been attributed to other organisms, or to unknown causes, were classified as 
probable cases of tularemia in retrospect (82, 103).  
By 1937 6,149 cases of human tularemia had been documented in the U.S. (55), a 
number that peaked with 2,291 cases of tularemia reported in 1939 alone (16). However, 
cases were rare in New England, which was attributed to the absence of cottontail rabbits in 
that region (55). While early reports of tularemia implicated rodents as having an important 
role in the transmission of tularemia to man, Jellison and Parker reported that approximately 
90% of human cases were the result of contact with infected lagomorphs, particularly 
cottontail rabbits, and the remaining 10% of cases included transmission by arthropod 
vectors, rodents, sheep and other animals (56). In the 1930s massive numbers of rabbits were 
imported to New England from Missouri, Kansas and Oklahoma, areas of endemic tularemia, 
for hunting purposes (55). Since that time tularemia has been seen in New England. 
Tularemia is now endemic on Martha’s Vineyard, Massachusetts, the site of the only known 
outbreaks of primary pneumonic tularemia in the U.S. (70). 
 
Routes of exposure and types of disease 
I know of no other infection of animals communicable to man
 
that can be acquired 
from sources so numerous and so diverse.
 
In short, one can but feel that the status of 
tularemia, both
 
as a disease in nature and of man, is one of potentiality.—R. R. Parker (76) 
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 Tularemia is caused by the small gram-negative coccobacillus, Francisella 
tularensis. About 200 cases of tularemia occur each year in the United States (CDC). The 
disease is endemic throughout much of Europe, where large outbreaks involving hundreds of 
cases occur periodically (110).  Humans contract tularemia via a number of routes. The most 
typical naturally occurring form of the disease is ulceroglandular tularemia, which results 
from skin or mucous membrane contact with F. tularensis (2). Exposure may occur by direct 
contact with an infected animal (31, 118), or through the bite of an arthropod vector (2, 62, 
67). An ulcer develops, and if untreated the draining lymph nodes may enlarge and suppurate 
(109). Oculoglandular and oropharyngeal tularemia result from bacterial contact with the 
eyes, or ingestion of contaminated food or water, respectively (9, 10, 51, 91). Primary 
pneumonic tularemia results from inhalation of F. tularensis, while dissemination from initial 
sites of infection to the lung can result in secondary pneumonic tularemia (30, 70). Patients 
with pneumonic tularemia experience symptoms that may include sporadic fever, fatigue, 
chills, malaise, myalgia, headache, and nonproductive cough (32). Chest X-rays are usually 
normal in the early stage of infection, then may begin to show infiltrate and pleural effusion 
as the disease progresses (70). Patients with typhoidal tularemia present with generalized 
symptoms, similar to those of pneumonic tularemia, but without an identifiable route of 
infection (30). The non-specific nature of symptoms, which can overlap with those caused by 
illnesses such as Rocky Mountain Spotted Fever and Lyme Disease, complicates the 
diagnosis of tularemia (70).  The overall mortality rate due to tularemia in the United States 
is less than 2%. Untreated, that rate rises to 5-15% for infections with virulent strains, and 
30-60% for pneumonic and typhoid forms of tularemia (30). 
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Biodefense 
Francisella tularensis is an ideal candidate for development as a biological weapon 
due to its very low infectious dose and ability to cause disease following inhalation, and as 
such was designated a Category A select agent by the CDC (93). Japan’s infamous research 
unit 731 studied the effects of Francisella and other agents on human subjects in the years 
leading up to and including World War II (52).  Francisella was a part of the biological 
weapons programs of both the United States and the former USSR during the cold war (5, 22, 
30, 101) Ken Alibek, a former Soviet bioweapons researcher, suggests that F. tularensis was 
used offensively against the Germans during WWII (5). However, evidence suggests that the 
large outbreaks of tularemia during WWII were likely naturally occurring and related to ideal 
conditions for the disease that existed during wartime (39). Alibek also claims that the 
Soviets continued to develop Francisella as a biological weapon into the 1990s (5).  
A World Health Organization (WHO) model developed in 1969 predicted that release 
into the air of 50 kg of virulent F. tularensis over an area inhabited by 5 million people 
would result in 250,000 illnesses and 19,000 deaths (1). Using this model the CDC 
extrapolated the economic impact of such an attack, and predicted it to be $5.4 billion for 
every 100,000 people exposed (58). The Biological and Toxin Weapons Convention, which 
prohibits development of biological weapons, has been in effect since 1975 and signed by 
144 countries (88). However, recent world events including the September 11, 2001 terrorist 
attacks, and the intentional dispersion of Bacillus anthracis spores through the U.S. mail that 
same year (4), have lead to renewed interest in bioterrorism preparedness research. 
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Strains and Distribution 
There are four subspecies of Francisella tularensis. F. tularensis subsp. tularensis 
(Type A) and F. tularensis subsp. holarctica (Type B) are implicated in human disease. The 
two other subspecies, mediasiatica, and novicida, are considered non-virulent in immune 
competent people. 
F. tularensis subsp. tularensis (Type A), found primarily in North America, is highly 
virulent in humans and animals. The highest incidence of tularemia in the United States is 
seen in Arkansas and Missouri, in the eastern parts of Oklahoma and Kansas, in southern 
South Dakota and Montana, and on the island of Martha’s Vineyard in Massachusetts (3). 
Inhalation of as few as 10 organisms of a virulent type A strain can cause disease (97). Two 
subpopulations of Type A  F. tularensis have been defined by pulsed-field gel 
electrophoresis that differ in distribution, transmission and disease outcome (106). These 
subpopulations are designated Type A-east for those isolates coming from states transecting 
or east of the 100
th
 meridian, and Type A-west for those from states west of the 100
th
 
meridian (106).  Infection is most frequently associated with ticks (type A-east) or biting flies 
(type A-west), or exposure to infected cats or lagomorphs (106). There is a marked difference 
in fatality rates between the type A subpopulations, with type A-east being 14% and type A-
west being 0% (106).  The less virulent F. tularensis subsp. holarctica (Type B) is found 
throughout Europe, Asia and North America. The geographic distribution of type B cases in 
the United States tends to fall along major waterways and areas with high rainfall (106), and 
is associated with tick bites and exposure to rodents or cats (106). Tularemia caused by type 
B strains is widely distributed throughout Europe and Asia, with highest incidences occurring 
in the Nordic region, and the former USSR (108). European tularemia transmission has been 
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associated with rodents, lagomorphs, ticks, horse flies and mosquitoes, as well as with 
contaminated water supplies (86, 103). Analysis of all clinical isolates of F. tularensis 
submitted to the Centers for Disease Control and Prevention (CDC) between 1964 and 2004 
indicated that of American tularemia cases 66% were Type A and 34% were type B isolates 
(106). 
The live vaccine strain (LVS) is an attenuated type B strain that was created by 
repeated passage of a virulent strain. It is not approved for general use in the United States, 
as the basis of its attenuation is unknown (89). However, LVS does cause a tularemia-like 
disease in mice, and is used as a model for research purposes (8). Francisella tularensis 
supsp. novicida (F. novicida), while not virulent in immune competent humans also causes a 
tularemia-like disease in mice, and is also used in tularemia research. 
 
Genomic Analysis and Genetic Tools 
In order to discover the means by which pathogenic bacteria cause disease it is useful 
to have tools available to genetically manipulate the bacteria. While spontaneous or 
chemically induced mutants may yield phenotypes of interest, it is very difficult to identify 
the gene(s) interrupted. Therefore, it is ideal to be able to introduce random mutations, with 
associated markers, into the genome. Early mutant libraries were constructed in F. novicida 
using strategies that involved manipulation and reintroduction of chromosomal DNA 
fragments. Cassette mutagenesis allowed introduction of antibiotic resistance markers into 
restriction sites of chromosomal DNA fragments, which were then transformed into F. 
novicida (7). Antibiotic resistant transformants, which contained a genomic copy of the 
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mutated gene resulting from homologous recombination, were used to screen for a phenotype 
of interest, such as the inability to replicate in macrophages.  Shuttle mutagenesis allowed 
more complete genome coverage when introducing mutations by using transposon insertions 
to randomly insert into genes rather than antibiotic resistance markers ligated into restriction 
sites (37). Transposon mutagenesis was carried out in E. coli on 5-10 kb fragments of F. 
novicida genomic DNA ligated into pUC18. Mutagenized plasmids were then transformed 
into F. novicida, where they were forced to integrate into the chromosome due to inability of 
the plasmid to replicate in Francisella, and transformants screened for the phenotype of 
interest (27, 48). It was subsequently reported that the Tn10 and Tn1721-based transposon 
insertions created  by these shuttle mutagenesis strategies are not stable in Francisella (64). 
These early strategies were ineffective in human pathogenic strains of Francisella. 
Of the predicted genes in Francisella subspecies novicida, holarctica and tularensis, 
86.4% are common to all three (90). When comparing the nucleotide sequences of those 
common genes, novicida and LVS are 97.8% identical; novicida and Schu S4 are 98.1% 
identical, and LVS and Schu S4 are 99.2% identical (90). In spite of the genetic similarity 
between these species, it is obvious based on variability in infectious dose, disease severity, 
and host range that there are important differences between these strains. As the genetic 
determinants of Francisella virulence have begun to emerge, inter-species differences in 
some of those loci have been observed.   Examples of virulence related genes/operons that 
differ between subspecies include the pathogenicity island (pmcA and pdpD) and T4P/T2SS 
related genes (pilAEV and pilT), both of which are described in the following sections. For 
this reason, it is crucial that genetic tools be available for use in Francisella subspecies other 
than novicida. Chapter 5 describes our development of a strategy to create stable F. 
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tularensis LVS transposon insertion mutants (59). This method has now been used 
successfully in F. tularensis Schu S4 as well (83).  
In addition to the creation of random mutant libraries, methods have been developed 
for the disruption of targeted genes by allelic exchange. This has been achieved using a one 
step strategy involving the introduction of PCR products consisting of upstream and 
downstream regions of homology to the gene of interest flanking an antibiotic resistance 
cassette (64). This method has only been used successfully in F. novicida, and the efficiency 
of allelic exchange is low (37). Suicide vectors have been used in type A (66, 113) and B (45, 
66, 79) strains, as well as F. novicida (15, 17), to generate either marked or unmarked gene 
deletions. Merodipliods created by single crossover events resolve efficiently in F. novicida 
(84), while sacB counter selection for second crossover events can be used in subspecies 
holarctica and tularensis (45, 66). Rodriguez et al. recently described the development of 
group II introns for use in subspecies tularensis, holarctica, and novicida (87). Group II 
introns are mobile genetic elements composed of excised intron RNA and intron encoded 
reverse transcriptase (57). This catalytic RNA inserts into a target DNA sequence by a 
process known as retrohoming, and by designing introns that recognize sequence from genes 
of interest targeted mutations can be created (57).   This strategy has the advantage of 
allowing simultaneous and efficient targeting of duplicate genes, such as the pathogenicity 
island genes in the human pathogenic Francisella strains (87). 
 
Genes related to pathogenesis 
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Due to easier genetic manipulation, and the lack of tools available for use in the other 
strains of Francisella, much of the early Francisella pathogenesis work was done in F. 
novicida. Francisella tularensis is a facultative intracellular pathogen, and the genes 
identified for virulence are largely associated with the ability to replicate in macrophages. A 
spontaneous mutation of F. novicida that decreases the organism’s ability to replicate in 
macrophages was mapped to an operon that was termed mglAB(14). MglA expression peaks 
during exponential phase growth, and is induced during growth in macrophages and amoebae 
(13, 65). MglA has homology to the E. coli transcriptional regulatory protein SspA, and 
regulates the expression of genes potentially involved in pathogenesis (17, 65). PmrA also 
regulates a number of F. tularensis genes, and a F. novicida pmrA mutant is attenuated in 
macrophages and mice (12). 
The Francisella pathogenicity island (FPI) is a 30 kb section of genomic DNA, 
surrounded by transposable elements, and containing a lower G+C content than the rest of 
the genome (75). Expression of FPI genes is regulated by both MglA and PmrA. The F. 
novicida pathogenicity island contains 17 ORFs, including iglABCD and pdpABC, which are 
predicted to form two convergently transcribed operons (12). Type A and B strains of 
Francisella contain nearly identical, but duplicate, copies of the FPI (75). The notable 
differences between the subspecies lie upstream of iglA, where F. novicida contains pmcA 
and pdpD genes. The type A strain Schu4 contains 3 small ORFs in place of pmcA, and pdpD 
contains a 150bp deletion, while in the type B strain LVS pmcA and the majority of pdpD are 
missing (74).  
Mutants of many FPI genes have been evaluated for their effect on pathogenesis, 
which is associated with the inability of these mutants to replicate in macrophages. F. 
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novicida iglA and iglC mutants are defective for growth in macrophages (28, 46, 96). IglC 
was first identified as a 23 kd LVS protein that was up-regulated during growth in 
macrophages or after exposure to hydrogen peroxide, and the LVS iglC mutant is unable to 
replicate in macrophages and is avirulent in mice (44, 45). A F. tularensis Schu S4 iglC 
mutant is avirulent in mice as well (113). F. novicida pdpA and pdpB mutants are defective 
for replication in macrophages and are attenuated in mice (75, 111). The mechanisms by 
which these gene products cause disease largely remain to be elucidated.  
Genes outside the FPI that are required for survival and replication in the macrophage 
have been identified as well. A gene necessary for survival and replication in macrophages 
and epithelial cells, as well as virulence in mice, ripA, will be described in detail in Chapter 
4. ClpB is a heatshock protein which is responsible for disaggregating and reactivating 
proteins in E. coli (119), and is involved in stress resistance in a number of bacteria (19, 
104). F. novicida mutant screens have identified clpB as necessary for replication in 
macrophages (46, 111). A LVS clpB mutant exhibits increased sensitivity to stess (i.e., heat, 
low pH, ethanol, oxidative stress), and decreased replication in macrophages compared to 
wildtype LVS and is severely attenuated in mice (73, 107). A mutant of another heat shock 
protein gene, htpG, which encodes an hsp90 chaperone homologue, was deficient for 
virulence in mice and replication in macrophages (114). A LVS mutant in a gene involved in 
LPS O-antigen biosynthesis, wbtA, is serum sensitive, unable to replicate in macrophages,  
and attenuated in mice (85, 100). Interestingly, O-antigen mutants in F. novicida were serum 
sensitive and attenuated in mice, but were able to replicate normally in macrophages (112). 
Additionally, mice immunized with LPS from a type A strain were protected against 
infection with a type B strain, and mice immunized with F. novicida LPS are protected 
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against F. novicida infection, but neither group are protected against heterologous challenge 
(112).  Other F. novicida genes required for growth in macrophages and disease in mice 
include dsbB, a gene whose product is used for proper folding of periplasmic proteins in E. 
coli, as well as genes which contribute to purine and pyrimidine biosynthesis (46, 111). 
Genes required for virulence that are not required for replication in the macrophage 
have been identified as well. Two mutants identified in a F. novicida in vivo negative 
selection screen, FTT0748 and FTT0584, replicate normally in macrophages, but are 
severely attenuated in mice. These mutants induce rapid cell death in macrophages in an 
ASC and Caspase-1 dependent manner, indicating that these gene products may be 
responsible for modulating the host immune response to intracellular Francisella (114). F. 
tularensis tolC, is predicted to encode a protein whose homologues in other organisms form 
components of a multi-drug efflux pump or type I secretion system(29, 63). An LVS mutant 
of tolC is able to replicate in macrophages, but is severely attenuated in mice inoculated 
intradermally (42).  
In contrast to genes that contribute to the virulence of Francisella, pepO may have 
the opposite effect. PepO is a zinc metalloprotease that is transcriptionally regulated by 
MglA in F. novicida (50). Interestingly, pepO mutants are hyper-virulent in mice, possibly 
due to the absence of a potent vasoconstrictor that is formed by the PepO mediated cleavage 
of pro-endothelin (50), and which could limit bacterial dissemination. Only F. novicida 
contains a version of this gene predicted to encode both a secretion signal and an intact 
protease domain, which could potentially contribute to this organism’s status as non-
pathogenic in humans.  
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In vivo screens have identified a number of additional genes that are necessary for F. 
novicida and LVS virulence in mice (107, 114). The majority of these virulence determinants 
remain to be characterized, but should provide a wealth of information as to the mechanisms 
by which Francisella causes disease.  
 
Protein Secretion in F. tularensis  
All bacteria need to secrete proteins for a variety of reasons, such as acquisition of 
nutrients and production of outer membrane structures. Bacteria use the general secretory 
pathway (Sec) to translocate proteins with the appropriate signal sequence across the 
cytoplasmic membrane. Gram-negative pathogens frequently make use of secreted toxins or 
virulence factors, and have evolved a variety specialized systems to translocate these proteins 
across the outer membrane, and in some cases directly into the host cell (reviewed in (40). 
The F. tularensis genome does not contain homologues to type III secretion systems 
(T3SS) and type IV secretions systems (T4SS), which are utilized by many pathogens for 
secretion of virulence factors. T3SS are responsible for the ability of Salmonella and Shigella 
spp. to invade nonphagocytic cells (26). F. tularensis does contain two genes, tolC and ftlC, 
whose products are homologous to E. coli TolC, which could encode a protein that functions 
as part of a T1SS, or participates in efflux of toxins. LVS mutants tolC and ftlC demonstrate 
increased susceptibility to drugs and detergents, and the tolC mutant is attenuated in mice  
(42).  
There is considerable overlap among genes used for Type IV pili (T4P) formation and 
those that play a role in type II secretion. The type A Schu S4 genome contains homologues 
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to all genes necessary for T4P formation (35). The F. novicida genome contains homologues 
to all genes as well, though the C-terminal half of the pilA gene is significantly altered, as is 
the intergenic region of the pilAEV gene cluster (35).  Some F. holarctica (type B) strains 
lack pilA, and all appear to lack functional copies of the downstream genes pilE, pilV, and 
pilT due to nonsense mutations (36, 80). LVS is lacking functional copies of both the pilAEV 
genes and pilT (36). Protein secretion is abrogated in transposon insertion mutants of F. 
novicida pilB, pilC and pilQ, which are respectively homologues of an ATPase, an inner 
membrane protein, and a secretin involved in T4P secretion.  The pilA gene is also necessary 
for in vitro protein secretion in F. novicida (50). A pilA negative type B strain is able to 
replicate normally in macrophages, but is attenuated in mice when given subcutaneously 
(36). Similarly, a F. novicida pilC mutant is able to replicate normally in macrophages (50). 
Interestingly, in contrast to the attenuated type B mutant, the F. novicida pilC mutant is 
hyper-virulent when given to mice intradermally (50).  Type A and B strains contain 
mutations in the pepO gene that result in a deletion of the secretion signal, while type B 
strains also contain a premature stop codon that eliminates the protease domain from PepO 
(50). It is hypothesized that this increase in virulence is due to failure to secrete the PepO 
protease that is predicted to activate a vasoconstrictor, thereby limiting dissemination. 
Hager et al. suggest that F. novicida protein secretion takes place via the T4P system, 
rather than the T2SS, since there are no Francisella homologues to gspC, gspM and gspL, 
genes necessary to meet the definition of type II secretion (50, 77). This idea is not 
unprecedented, as Vibrio cholerae secretes a virulence factor, TcpA, via a T4P system (60). 
Whether these genes are also used to produce type IV pili seems to be strain dependent and 
still open to investigation. Pili have not been identified on Type A strains or F. novicida, 
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though the expression of pilA from both induced pili formation in a Neisseria system (35). 
T4P-like structures have been identified microscopically on LVS, however this strain does 
not contain a functional pilA gene, so the exact nature of these structures remains to be 
elucidated (41).  
There is speculation that the F. tularensis pathogenicity island may encode a type VI 
secretion system.  IglA and iglB homologues are present in a number of plant and animal 
pathogens, where they invariably appear together and their order is conserved (74). IglA and 
iglB homologues cluster into a group of genes that include members with IcmF motifs (74). 
IcmF-associated homologous proteins (IAHPs) are associated with T6SSs in some 
organisms. Two other PI genes, pdpB and pigF, also show homology with IAHPs (74). 
However, it remains to be determined whether PI genes encode a T6SS system in 
Francisella.   
 
Respiratory Tularemia and Lung Biology 
  Although the primary type of naturally occurring tularemia is ulceroglandular (2), the 
low infectious dose of as few as 10 organisms by the respiratory route (97), along with the 
mortality rate of 30-60% for untreated pneumonic infections with a type A strain (30), have 
lead to our lab’s focus on respiratory tularemia. The potential for aerosol dissemination of 
this organism necessitates research to understand the mechanisms of respiratory tularemia. 
A person inhales about 10,000 liters of air each day (117). This air, which passes 
through the airways (trachea, bronchi, bronchioles) to the alveoli, may contain particulate 
matter, bacteria and viruses. Ciliated epithelial cells coated with mucus line the airways, and 
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make up the “mucociliary escalator”, which moves particles captured in mucus up and out of 
the airway by the action of the cilia (105, 117). The airways terminate at the alveoli, the site 
of gas exchange with the blood. Alveolar macrophages patrol the alveolar space, where they 
phagocytose bacteria and modulate the host immune response (68).  The alveoli are made up 
of type I and type II alveolar epithelial cells. Type I cells (ATI) are responsible for gas 
exchange, and make up about 95% of the surface area of the alveolar epithelium (69). Type II 
cells (ATII) are the progenitors of ATI cells, make up 5% of the surface area of the alveolar 
epithelium, and are responsible for the production and secretion of pulmonary surfactant 
(69). Surfactant is composed primarily of phospholipids, along with the surfactant proteins 
SP-A, SP-B, SP-C and SP-D (117). Surfactant phospholipids reduce the surface tension at the 
lung’s air-liquid interface, allowing respiration. SP-B and SP-C are small hydrophobic 
proteins that help to stabilize the surfactant film (69, 117). SP-A and SP-D are collectins 
(collagen-containing C-type lectins) capable of binding a number of microorganisms leading 
to several possible outcomes, including bacterial aggregation, lysis, and opsonization for 
phagocytosis, and modulation of the immune response (61, 117). Both macrophages and 
ATII cells express surfactant protein receptors (61). ATII cells employ these receptors for the 
re-uptake of surfactant, which is constantly being recycled in the lung (116). 
Most pathogens that are able to cause disease in the lung do so by virtue of their 
ability to survive in macrophages. However, there is some evidence of pathogens that also 
invade alveolar epithelial cells. Mycobacterium tuberculosis, considered to primarily infect 
macrophages, is capable of invading and replicating in the alveolar epithelial cell line A549 
(38). While in vivo uptake and replication has not been demonstrated, bacterial DNA is found 
in ATII cells of human lung tissue (38). Burkholderia cepacia invades ATII cells both in 
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vitro and in vivo (18, 21). Chapter 1 and 2 of this work describe the ability of F. tularensis to 
invade and replicate in ATII cells both in vivo and in vitro. 
A primary function of macrophages is to engulf bacterial cells and other foreign 
particles (54, 92). F. tularensis invasion of and trafficking within macrophages has been 
characterized, and is described below. However, invasion of epithelial and other host tissue 
cells that lack professional phagocytic receptors requires bacterially mediated exploitation of 
host cell cytoskeleton and signaling to gain entry (26, 33, 34). Pathogens that invade 
nonphagocytic cells, such as Yersinia pseudotuberculosis, Listeria monocytogenes, and 
Salmonella spp. have developed strategies to gain access to these cells, and to survive 
intracellularly (26). Chapter 3 describes our lab’s efforts to characterize F. tularensis entry 
into lung epithelial cells and trafficking inside these cells. 
 
F. tularensis uptake by the macrophage 
Much of the research on F. tularensis pathogenesis to date has focused on the 
interaction of Francisella with the macrophage, as many of the genes that have been 
identified as being required for virulence are related to surviving in these cells. Francisella is 
taken up by macrophages by a unique process that has been termed looping phagocytosis 
(24). LVS and type A clinical isolates of F. tularensis have been identified being taken up by 
human macrophages by this process, which involves the formation of a single pseudopod 
loop which encircles the bacteria before fusing with the plasma membrane to form a large 
vacoule. This vacuole shrinks once the bacterium has been internalized by the macrophage. 
This uptake mechanism differs from the well characterized zipper and trigger mechanisms, as 
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well as from the coiling phagocytosis previously described for Legionella pneumophila (53). 
Both live and dead F. tularensis is taken up by looping phagocytosis, and uptake is 
dependent upon actin polymerization and PI3 kinase signaling (23).  However, oxidation of 
bacterial carbohydrates results in uptake that microscopically resembles conventional 
receptor-mediated (zipper) phagocytosis, suggesting that bacterial LPS or capsular material 
may mediate looping phagocytosis (23).  
Invasion frequency of macrophages is far lower in the absence of fresh serum, and C3 
deficient serum does not promote uptake, indicating the involvement of the macrophage 
complement receptor (CR3) in uptake of LVS and type A strains by human macrophages (23, 
98). Opsonization with fresh serum leads to human macrophage uptake of F. novicida via 
complement receptors and Fcγ receptors (11, 98). Competitive inhibition of the macrophage 
mannose receptor (MR) decreases uptake of both LVS and F. novicida by human 
macrophages the absence of serum opsonization, indicating a MR role in phagocotosis (11, 
98). F. novicida phagocytosis by human macrophages is also increased when bacteria are 
pretreated with surfactant protein A (SP-A) (11). SP-A is a collectin produced in the lung, 
and will be described in greater detail in the lung biology section. Phagocytosis of LVS by 
the mouse macrophage-like cell line J774, is mediated by class I and II A scavenger receptors 
(SRA) and CR3 (81). Of interest, Fcγ receptors do not appear to have an effect on 
Francisella phagocytosis in J774 cells (81), and this cell line does not express mannose 
receptors (98). In conclusion, the suite of receptors responsible for the uptake of the various 
species of Francisella by macrophages include CR3, SRA, MR, Fcγ and SP-A receptors. 
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F. tularensis lifestyle in the macrophage 
Once particles are taken up by phagosomes they are set on a path toward eventual 
destruction by lysosomal enzymes (47, 99). Nascent phagosomes interact with components 
of the endocytic pathway resulting in phagosome maturation as evidenced by acquisition of 
membrane markers. Markers are acquired in a sequential manner demarcating progression 
from phagosome to early endosome, late endosome, to lysosome. During this maturation 
process the contents of the vacuole become increasingly acidic and hydrolytic, leading to the 
digestion of the contents.  
Bacterial pathogens have evolved strategies to survive the hostile environment of the 
phagosome. Some, such as Ehrlichia chaffeensis and Mycobacterium spp. are able to survive 
in an endocytic vacuole by halting maturation of the vacuole and fusion with the lysosome 
(49). Others, such as Legionella pneumophila and Brucella abortus , modify the vacuole to 
create a unique intracellular niche separate from the endocytic pathway (49). Still others, 
such as Listeria monocytogenes and Shigella flexneri, survive by escaping the endocytic 
vacuole to replicate in the cytoplasm (49). 
Francisella taken up by rodent or human macrophages is contained within a 
membrane bound vacuole which rapidly acquires early endosome markers (EEA1), then 
eventually acquires late endosome markers (LAMP1 and LAMP2), before escaping into the 
cytoplasm to replicate (6, 20, 25, 43, 95). The Francisella containing vacuole does not 
acquire lysosomal markers, such as cathepsin D (95). This same general path is followed by 
F. novicida, type A and type B strains of Francisella. The timing of escape from the vacuole 
into the cytoplasm has been reported as occurring between 1 and 6 hours post-infection (20, 
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25, 43, 95). This wide range can largely be attributed to how researchers choose to define 
escape from the vacuole. Those that use a flow cytometry based assay in which bacteria are 
defined as cytoplasmic if they are accessible to cytoplasmically delivered antibody report 
95% escape by 60 minutes (20), while those that define escape as less than 50% of the 
circumference of a particular intracellular bacteria surrounded by membrane report escape 
times of 3 to 6 hours (25).  
There is some disagreement as to whether the vacuole becomes acidified before 
escape into the cytoplasm. Clemens et al. indicate that a type A strain resides in a vacuole 
that does not become significantly acidified in human macrophages (25). However, Santic et 
al. recently reported that F. novicida containing vacuoles in human macrophages become 
acidified via transient acquisition of the proton vATPase pump 30-60 minutes post-infection, 
and that this acidification is vital to bacterial escape into the cytoplasm (94). F. novicida 
mutants of the pathogenicity island gene iglC, or its regulator mglA, are unable to prevent 
lysosomal fusion, and are unable to escape the phagosome (96). Phagosomes containing the 
iglC mutant retain the proton vATPase pump, and go on to lysosomal killing (94, 96). It is 
possible that these conflicting results regarding vacuole acidification could be attributed to 
the different strains being tested, or more likely, to the timing of the experiments. Those 
experiments demonstrating that there is no acidification of the vacuole were carried out 3 
hours post-infection (25), a time at which the vacuolar membrane is degraded and the 
vacuolar contents are likely in equilibrium with the cytoplasm; those showing acidification 
were done 30-60 minutes post-infection, a time at which the membrane is more likely intact 
(94). 
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Abstract 
Francisella tularensis replicates in macrophages and dendritic
 
cells, but interactions with 
other cell types have not been
 
well described. F. tularensis LVS invaded and replicated 
within
 
alveolar epithelial cell lines. Following intranasal inoculation
 
of C57BL/6 mice, 
Francisella localized to the alveolus and replicated
 
within alveolar type II epithelial cells. 
 
 
Text 
Francisella tularensis, the etiological agent of tularemia,
 
is a zoonotic pathogen with 
a broad host range, spanning from
 
protists to humans. The organism is transmitted to humans 
through
 
handling of contaminated material, insect bites, or inhalation (1, 10). It has been 
determined that contact with 25 or fewer
 
bacteria is sufficient to cause disease (16, 17). 
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Following
 
contact, the bacteria disseminate to the liver, spleen, and
 
lungs regardless of the 
initial transmission route (7, 10).  
The low infectious dose, myriad of transmission routes, broad
 
host range, and severity 
of disease caused by F. tularensis
 
led a number of nations to develop and stockpile this 
organism
 
as a biological weapon (9), yet little is known about the basis
 
of its pathogenesis or 
virulence. It has been reported that
 
macrophages and, potentially, dendritic cells serve as the 
primary
 
host cells for growth of Francisella in humans and other animals (6, 18). This 
conclusion is supported by the observations that
 
F. tularensis and other closely related 
Francisella species
 
survive and replicate in human and rodent macrophages (2, 5) 
 
and that 
many of the identified attenuating mutations impair
 
intramacrophage growth (3, 11, 12, 14, 
15).
 
 
Clearly, intramacrophage survival is an important virulence
 
property of Francisella. 
However, apart from one report of hepatocyte
 
association in infected liver (8), the potential 
contribution
 
of other host cell interactions to F. tularensis virulence and
 
pathogenesis remains 
untested. Given the severity of tularemia
 
acquired by inhalation, we sought to address this 
possibility
 
by using in vitro and in vivo models to examine whether Francisella
 
invades and 
replicates within epithelial cells of the lung.
  
 
Francisella tularensis LVS invades and replicates within lung epithelial cells in vitro.  
To determine whether Francisella could invade and replicate
 
within lung epithelial 
cells, in vitro invasion and replication
 
assays were performed using the human alveolar type 
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II (ATII)
 
epithelial cell-derived cell line A549 (ATCC), the mouse ATII
 
cell-derived cell line 
MLE-12 (ATCC), and the mouse lung epithelial
 
cell-derived cell line Tc-1 (ATCC). For 
comparison, the mouse
 
macrophage-like cell line J774A.1 (ATCC) was also used. 
Intracellular
 
bacteria were enumerated by a gentamicin protection assay. The
 
cell lines were 
grown to confluence in 24-well plates and inoculated
 
with F. tularensis LVS at a multiplicity 
of infection of 100:1.
 
Four hours after inoculation, the cells were washed with phosphate-
buffered
 
saline (PBS), and medium containing gentamicin (25 µg/ml)
 
was added to kill 
extracellular bacteria.
 
 
Intracellular organisms were recovered from all cell lines 6
 
and 24 h postinoculation 
(Figure 1A). The number of intracellular
 
organisms recovered 6 h postinoculation and the 
percentage of
 
infected cells varied among the lung epithelial cell lines,
 
with the fewest 
intracellular Francisella organisms recovered
 
from the human ATII cell line, A549. The 
percentage of infected
 
epithelial cells ranged from 0.2% of A549 cells to 17% of Tc-1
 
cells 
(Figure 2.1A). The number of intracellular bacteria recovered
 
from each lung epithelial cell 
line at 6 h was smaller than
 
the number recovered from J774A.1 cells, as was the percentage
 
of infected cells, indicating that entry into epithelial cells
 
may be a less efficient process than 
uptake by macrophages. 
The number of intracellular bacteria increased by an average
 
of 100-fold during the 
following 18 h in each cell line, representing
 
an intracellular doubling time of roughly 3 h 
(Figure 2.1A). Intracellular
 
localization and proliferation were confirmed using fluorescence
 
microscopy and digital image deconvolution (Figure 2.1B to E). From
 
6 to 24 h 
postinoculation, the relative increase of intracellular
 
bacteria within lung epithelial cells was 
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similar to that observed
 
within J774A.1 cells, indicating that F. tularensis LVS replicated
 
to 
the same degree within lung epithelial cells as in macrophages.
 
 
There are many reports of Francisella replicating within macrophages
 
in vitro, and 
here we report its ability to replicate within
 
cultured lung epithelial cells. Whereas some work 
has been done
 
to examine localization of Francisella in the liver (8), little
 
is known about the 
localization of inhaled Francisella in the
 
lung. Bosio and Dow recently reported that 
Francisella was associated
 
primarily with dendritic cells isolated from bronchioalveolar
 
lavage fluid of mice 1 hour after inhalation (6). However, the
 
localization of bacteria in lung 
tissue throughout the course
 
of infection has not been addressed.
  
 
Following inhalation, Francisella localizes to the alveolus.  
To determine the localization of Francisella in the airway following
 
inhalation, 
anesthetized 6- to 8-week-old female C57BL/6 mice
 
were inoculated intranasally with 10
5
 
CFU of F. tularensis LVS
 
expressing green fluorescent protein (GFP) suspended in 50 µl
 
of 
PBS. (All mouse work was performed according to IACUC-approved
 
protocol.) 
Immunofluorescence analysis was performed on formalin-fixed
 
and paraffin-embedded tissue 
sections obtained from nasal turbinates,
 
trachea, and lungs harvested 1, 3, and 7 days 
postinoculation.
 
No bacteria were observed in turbinates or trachea. In the lung,
 
few bacteria 
associated with the apical surface of bronchial
 
epithelial cells, while the majority colocalized 
with alveolar
 
cells (Figure 2.2). Fluorescence imaging of sequential vertical
 
planes revealed 
that most infected alveolar cells contained
 
multiple bacteria throughout the cytoplasm, 
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indicative of intracellular
 
replication (data not shown). Bacterial replication within ciliated
 
or 
nonciliated (Clara) bronchial epithelial cells was not observed.
 
The absolute number of 
bacteria (Figure 2.2D) and the number of
 
infected alveolar cells increased by day 3 (Figure 
2.2B). By day
 
7, F. tularensis within the lung was widespread but remained
 
exclusively in the 
alveolus (Figure 2.2C). Throughout the course
 
of infection, the amount of extracellular space 
observed in
 
the network of alveolar cells decreased, causing the alveolar
 
cells to appear more 
condensed (Figure 2.2). 
 
Inhaled Francisella colocalizes to and replicates within ATII cells in vivo.  
Given that Francisella invaded and replicated within ATII-derived
 
cell lines in vitro, 
we probed infected lung tissue sections
 
with antibodies to the nonsecreted surfactant protein 
precursors
 
proSP-B and proSB-C (Chemicon) to determine whether Francisella
 
localized to 
and replicated within ATII cells in vivo following
 
inhalation. proSP-B is produced by ATII 
cells and nonciliated
 
bronchiolar Clara cells (13), whereas proSP-C is produced by
 
ATII cells 
exclusively (4). Three days following inoculation,
 
the majority of alveolar cells associated 
with F. tularensis
 
also bound antibodies to the nonsecreted surfactant protein
 
precursors 
proSP-B and proSB-C (Figure 2.3A to D). Some cells associated
 
with bacteria were not 
positive for proSP-B or proSP-C, indicating
 
that Francisella interacts with other cell types in 
the lung
 
following inhalation.
 
 
In addition to the colocalization with proSP proteins, microscopy
 
of sequential 
vertical planes confirmed that bacteria were inside
 
infected ATII cells (data not shown). 
Rabbit antibody specific
 
for ß-tubulin (Abcam) did not colocalize with F. tularensis
 
(Figure 
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2.3E), indicating that the colocalization of Francisella
 
with rabbit proSP antibodies was not 
due to bacteria nonspecifically
 
binding rabbit antibodies, nor did the proSP antibodies cross-
react
 
with cultured Francisella organisms (data not shown). These
 
collective data 
demonstrate that F. tularensis replicates within
 
ATII cells following inhalation and the 
proportion of ATII cells
 
harboring bacteria increases during the course of pneumonic
 
tularemia.
 
 
Bacteria were also observed in probed sections that did not
 
colocalize with proSP-B 
and proSP-C (Figure 2.3), indicating that
 
ATII cells are not the only alveolar cell type 
harboring replicating
 
Francisella. Macrophages and dendritic cells have been reported
 
as 
potential host cells for replicating Francisella organisms (2, 5, 6). Due to difficulties in 
staining for surface macrophage
 
and dendritic cell markers in embedded lung sections, we 
utilized
 
dispase digestion of infected mouse lungs to stain for surface
 
markers and also to 
assess our results from the embedded tissue
 
staining.
 
 
Three days after inoculation with LVS expressing GFP, lungs
 
were infused and 
incubated with the neutral protease dispase
 
(BD Biosciences). Digested tissue was washed in 
PBS and subsequently
 
filtered through 40- and 20-µm-pore-size mesh. Staining
 
with 
fluorescently labeled antibody specific for the surface
 
markers F4/80 (eBioscience) and 
CD11c (eBioscience) was performed
 
prior to fixation with 4% paraformaldehyde. Staining 
for the
 
intracellular markers proSP-B and proSP-C occurred following
 
fixation and required 
the use of Cytoperm (BD Biosciences) to
 
permeabilize the cells. F. tularensis LVS was 
observed within
 
cells expressing F4/80, CD11c, proSP-B, and proSP-C (Figure 2.4),
 
37 
 
indicating that following inhalation, bacteria survive and replicate
 
within macrophages, 
dendritic cells, and ATII cells. 
Here we report that in addition to replicating within macrophages
 
and dendritic cells, 
F. tularensis invades and replicates within
 
alveolar type II epithelial cells, indicating that 
interaction
 
with these cells following inhalation may be an important component
 
of 
pneumonic tularemia. Future work will analyze the proportion
 
of various cell types that are 
infected in the lung as well
 
as attempt to identify the contribution of ATII cell invasion
 
and 
replication to the disease progression of pneumonic tularemia.
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Figure 2.1. F. tularensis LVS invades and replicates within ATII cell lines in vitro. (A) 
Intracellular bacteria recovered from A549, MLE-12, Tc-1, and J774A.1 cells 6 and 24 h 
postinoculation. The percentages above the bars represent percentages of infected cells. (B 
and C) Fluorescence imaging of A549 cells inoculated with GFP-expressing LVS 6 h (B) and 
24 h (C) following inoculation. Cell borders were visualized by rhodamine-phalloidin 
(Molecular Probes) staining (red), and nuclei were visualized with 4',6'-diamidino-2-
phenylindole (DAPI; blue). (D and E) Fluorescence imaging of J774A.1 cells inoculated with 
GFP-expressing LVS (green) 6 h (D) and 24 h (E) postinoculation. Cell borders were 
visualized using biotinylated lectin from Lens culinaris and streptavidin-conjugated Alexa 
Fluor 647 (Molecular Probes) (red), and nuclei were stained with DAPI (blue). Intracellular 
replication experiments were carried out in triplicate; error bars represent standard deviations 
of the means. 
 
40 
 
 
Figure 2.2. F. tularensis localizes to the alveolus following inhalation. Mice were 
intranasally inoculated with 10
5
 CFU of F. tularensis LVS expressing GFP. One, three, and 
seven days postinoculation, lungs were harvested and prepared for immunofluorescence 
analysis. (A to C) Bacterial localization was determined by probing lung sections with a 
fluorescently labeled antibody to GFP (green). Nuclei were stained with DAPI (blue) to 
visualize lung cells. Representative images of the alveoli of infected mice 1 (A), 3 (B), and 7 
(C) days postinoculation. (D) Bacterial recovery from lungs 1, 3, and 7 days following 
intranasal inoculation with 10
5
 CFU LVS. Each bar represents mean recovery from three 
mice; error bars represent standard deviations of the means. 
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Figure 2.3. Following inhalation, F. tularensis LVS expressing GFP colocalized with proSP-
B and proSP-C, proteins produced by ATII epithelial cells. Bacterial localization was 
determined with a fluorescently labeled antibody to GFP (green). Nuclei were stained with 
DAPI (blue). Sections were probed with fluorescently labeled antibody to proSP-B (red) (A 
and B), proSP-C (red) (C and D) to identify ATII cells and ß-tubulin (red) (E). 
Representative images are from lung sections 3 days postinoculation. 
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Figure 2.4.  F. tularensis LVS expressing GFP colocalized with cells expressing the 
macrophage marker F4/80, the dendritic cell marker CD11c, and the ATII cell markers 
proSP-B and proSP-C. Nuclei were stained with DAPI (blue). Mouse lung cells were probed 
with fluorescently labeled antibody to F4/80 (red) (A and B), CD11c (red) (C and D), proSP-
B (red) (E), and proSP-C (red) (F). Representative images are from lung cells 3 days 
postinoculation. 
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APPENDIX 
 
Supplemental Methods for Chapter 2 
 
Immunofluorescence staining of tissues 
One, 3, and 7 days following intranasal-inoculation of female 6-8 week old C57BL/6 mice, 
infected tissues were aseptically removed and fixed in 10% neutral buffered formalin prior to 
paraffin embedding.  5 micron sections of nasal turbinates, trachea, and lungs were mounted 
to slides.  Prior to staining, slides were de-paraffinized with xylene and rehydrated through a 
series of washes with decreasing concentrations of ethanol followed by a 30 minute 
incubation in 95
o
C Target Retrieval Solution (DakoCytomation) pH=6.1.  Slides were 
blocked with 3% bovine serum albumin (BSA) in PBS++  (1mM CaCl2, 1mM MgCl2, 
pH=7.4) for 2 hours and primary antibody incubations were performed in 1% BSA in PBS++ 
overnight at room temperature.  Slides were washed 3X with PBS++ followed by incubation 
with secondary antibodies in PBS++ for 1 hour.  Slides were washed 3X with PBS++ and 
mounting media + DAPI (Vector) was added.  Probed sections were sealed with cover slips 
using nail polish.  All fluorescence microscopy was performed using a Zeiss Axioplan 2 
microscope. 
 
Cell culture and gentamicin protection assays 
A549, MLE-12, and J774 cells were cultured as described by ATCC.  Human macrophages 
were derived from peripheral blood by isolating adherent peripheral blood mononuclear cells 
from anti-coagulated venous blood.  Adherent cells were cultured in RPMI 1640 
44 
 
supplemented with 10% heat-inactivated fetal bovine serum and L-glutamine for two weeks 
to enrich for macrophages.  All in vitro gentamicin protection assays were performed with 
approximately 10
6
 cells per well in a 24-well tissue culture dish.  Bacteria were added at a 
multiplicity of infection of 100:1 in a volume of 200 μL per well.  Supernatants were 
aspirated and replaced with 1 mL of media containing gentamicin (25 μg/mL) to kill 
extracellular bacteria 2 hours post-inoculation (J774, human macrophages) or 4 hours post 
inoculation (A549, MLE-12).  Six and 24 hours post-inoculation cells were rinsed with PBS 
and scraped from the wells with sterile wooden applicator sticks, vortexed, diluted, and 
plated on chocolate agar for bacterial recovery.  All gentamicin protection experiments were 
performed in triplicate and standard deviations of the means were calculated and are 
represented by error bars.  Fluorescence microscopy was performed on in vitro cell cultures 
by growing cells on sterile glass cover slips.  Gentamicin was added to cells as described 
above.  At the indicated time points, cover slips were washed and fixed with 4% 
paraformaldehyde prior to antibody staining.  Following staining, cover slips were washed 
and mounted to slides with nail polish.   
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Abstract 
Background: Francisella tularensis causes systemic disease in humans and other 
mammals with high morbidity and mortality associated with inhalation-acquired infection.  
F. tularensis is a facultative intracellular pathogen, but the scope and significance of cell-
types infected during disease is unknown.  Methods: Using flow cytometry, we identified 
and quantified infected cell-types and assessed the impact of infection on cell populations 
following inhalation of F. tularensis U112, LVS, and Schu S4.  Results: Initially alveolar 
macrophages comprised over 75% of Schu S4- and LVS-infected cells whereas 
approximately 51% and 27% of U112-infected cells were alveolar macrophages and 
neutrophils, respectively.  After three days roughly half the Schu S4- and LVS- and nearly 
80% of U112-infected cells were neutrophils.  All strains infected interstitial macrophages, 
dendritic cells, monocytes and ATII cells throughout infection.  Macrophage, monocyte, and 
dendritic cell populations were reduced during U112, but not Schu S4, infection.
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Conclusions: These results demonstrate directly for the first time that F. tularensis is a 
promiscuous intracellular pathogen that invades and replicates within cell-types ranging from 
migratory immune cells to structural tissue cells.  However, the proportion of cell-types 
infected, and the cellular immune response evoked by the human pathogenic strain Schu S4 
differs from that of the human avirulent U112. 
 
Introduction 
Since 2001, there has been increased interest in understanding pathogens with 
virulence characteristics making them dangerous for purposeful release.  One such organism 
is the gram-negative bacterium, Francisella tularensis, the etiological agent of tularemia.  
Virulent strains of Francisella can cause incapacitating or lethal disease in humans, mice, 
and other mammals (24).  Tularemia can be acquired via insect-bites (14), handling infected 
animal carcasses (30), contaminated water (12) or inhalation (15).  Inhalation exposure 
results in the most acute, rapidly progressing, manifestation of disease (6).  When inhaled, as 
few as 10 organisms can cause a debilitating, and potentially fatal, infection in humans (22).   
Given the seriousness of inhalation-acquired tularemia, surprisingly little is known 
about Francisella biology in the host lung.  Within one hour after inhalation, Francisella is 
found in airway macrophages and dendritic cells (DCs) (3, 4).  However, infection of these 
cells does not trigger production of TNF-α or IL-6 (3, 4).  Instead, Francisella infection 
induces immuno-suppressive mediators such as TGF-β (3) and prostaglandin E2 (31) through 
yet unknown mechanisms.  F. tularensis also infects other cell-types important for host-
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defense against lung infections, such as monocytes (23), neutrophils (16), and alveolar type II 
(ATII) epithelial cells (10).  
Growth within host cells is recognized as an important aspect of Francisella 
pathogenesis, however the range and scope of cells infected throughout disease have not been 
determined.  In order to understand mechanisms pivotal to the virulence of this organism we 
identified and quantified the repertoire of infected lung cells and characterized the cellular 
immune response following inhalation of three different F. tularensis subspecies. 
 
Results 
Identifying Francisella-Infected Lung Cells 
U112, Live Vaccine Strain (LVS), and Schu S4 are commonly studied closely related 
F. tularensis strains that exhibit differences in host range, virulence, and host response (Table 
1).   Single cell suspensions prepared from whole lung digests of mice inoculated intranasally 
with Francisella strains expressing green fluorescent protein (GFP) were analyzed by flow 
cytometry and fluorescence microscopy to identify the host-cell niche occupied by these 
organisms.  GFP+ lung cells, indicating association with Francisella, were readily detectable 
by flow cytometry (Figure 3.1A).  Microscopic examination of  cells sorted from the high 
GFP+ population presented significant punctate GFP+ fluorescence, indicative of highly 
infected cells (Figure 3.1B), whereas low GFP+ cells had as few as 1 GFP+ bacterium 
indicating that cells containing a single bacterium could be detected by flow cytometry.  No 
GFP+ bacteria were observed in the negative population.  Projection images compiled from 
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multiple planes throughout the Z-axis of membrane-stained cells revealed that bacteria were 
intracellular (data not shown).   
To directly compare Francisella strains, we inoculated mice with 10
2
 - 10
3
 colony 
forming units (CFU) for each strain.  Actual dose ranges were 513-550 CFU for U112, 1100-
1260 for LVS, and 337-410 for Schu S4.  For each strain there were more infected cells 24 
hours post-inoculation than the initial inocula, indicating that bacteria had replicated within 
this time frame (Figure 3.1C).  It is unlikely that Francisella could have replicated 
intracellularly, killed host cells, and infected additional cells within 24 hours, so this result 
suggests that a significant degree of extracellular replication occurred concurrently with host 
cell infection.  From day 1 to day 3 post-inhalation, there was a significant increase in the 
number of infected lung cells for each strain (Figure 3.1C).  On day 3 there was a similar 
number of infected cells between mice infected with U112 and Schu S4.  Fewer GFP+ cells 
were observed in LVS-infected mice at day 3 (p<.05), potentially because LVS infection was 
better controlled by the innate immune system. 
 
Composition of the Francisella host cell niche 
To assess the suite of cells infected by Francisella following inhalation, we identified 
GFP+ cells with cell-type-specific staining patterns (Figure 3.2, Table 3.2).  Twenty-four 
hours post-inoculation the predominant infected cell-type in mice infected with U112 
(51.6%), LVS (76.9%), and Schu S4 (78.9%) were alveolar macrophages (Figure 3).  Other 
cell types infected at day 1 were interstitial macrophages (11.0% U112, 5.4% LVS, 6.2% 
Schu S4), CD11b
low/mid
 DCs (1.2% U112, 4.3% LVS, 2.0% Schu S4), and ATII cells (2.4% 
U112, 2.4% LVS, 6.0% Schu S4).  Only 0.2% of LVS-associated cells were neutrophils and 
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no Schu S4-associated neutrophils were observed on day 1.  In contrast, 27.3% of U112-
infected cells at day 1 were neutrophils.   
By day 3, neutrophils were the predominant infected cell-type for each strain (79.3% 
U112, 56.9% LVS, 56.2% Schu S4), although more prevalent in U112-infected mice (Figure 
3.3).  The percentage of infected cells that were alveolar macrophages decreased to 2.3% for 
U112, 18.0% for LVS, and 14.3% for Schu S4.  A higher fraction of Schu S4-infected cells 
(8.8%) at day 3 were monocytes than LVS (1.6%) or U112 (1.4%).   
 
Number of infected cells 
Examining the proportion of Francisella-infected cell-types in the lung gave us 
insight into the Francisella host-cell suite over time, but another important consideration for 
understanding inhalation tularemia is how the abundance of infected cells changes in the lung 
during the disease course.  Therefore, we determined the number of each cell-type infected at 
day 1 and 3 following inhalation.  There was a significant increase in the number of infected 
interstitial macrophages, CD11b
high
 DCs, monocytes, neutrophils, and ATII cells in mice 
infected with each strain between day 1 and day 3 (Figure 3.4B,D,E,F,G).  In contrast, the 
number of infected alveolar macrophages and CD11b
low/mid
 DCs increased from day 1 to day 
3 in mice infected with LVS or Schu S4, whereas the number of these cells infected with 
U112 was unchanged (Figure 4A,C).  Most strikingly, on day 1 following inoculation, there 
were 2,670±1,287 U112-infected neutrophils compared to 10±16 for LVS and none detected 
for Schu S4. (Figure 3.4F).  These data demonstrate that increasing numbers of alveolar 
macrophages and DCs continue to become infected from day 1 to day 3 following inhalation 
of LVS or Schu S4 but not during infection with U112.  Schu S4-infected lungs had more 
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infected monocytes than U112- or LVS- infected lungs indicating a potential propensity by 
this strain to infect these cells.   
 
Effects on cell populations during disease progression 
In addition to analyzing the number and proportion of infected cell-types, we 
determined how Francisella infection impacted total cell populations in the lung as disease 
progressed.  Strain U112 imparted a 2.4-fold decrease in the number of alveolar macrophages 
from day 1 to day 3 (Figure 3.5A).  LVS-infected mice displayed a more modest decrease in 
these cells from day 1 to day 3, but this difference was statistically significant (p<.05).  
Alveolar macrophage numbers in Schu S4- infected mice did not change significantly from 
day 1 to day 3.  We also observed more alveolar macrophages in lungs of mice infected with 
each strain at day 1 than from PBS control mice, but only in LVS-infected mice was this 
difference significant (p<.05). 
Similar to alveolar macrophages, DC populations significantly decreased from day 1 
to day 3 in U112-infected mice (Figure 3.5C,D).  CD11b
low/mid 
DCs decreased 2.3-fold and 
CD11b
high
 DCs decreased 1.8-fold from day 1 to day 3 in U112-infected mice.  A modest 
increase in CD11b
high
 DCs was observed for LVS-infected mice from day 1 to day 3, 
however the number of CD11b
low/mid 
DCs remained the same.  There was no significant 
change in the number of DCs in Schu S4-infected mice from day 1 to day 3.  No significant 
difference was observed between the number of DCs from infected mice at day 1 and PBS 
control mice.  
There was no significant difference in the number of monocytes on day 1 following 
infection with each strain compared to PBS control mice (Figure 3.5E).  The number of 
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monocytes increased significantly in LVS- and Schu S4-infected mice from day 1 to day 3, 
whereas U112-infected mice had fewer monocytes in the lung over time.  
Lungs from LVS- and Schu S4-infected mice had more interstitial macrophages at 
day 3 than day 1, while U112-infected mice displayed no significant change in interstitial 
macrophage numbers (Figure 3.5B).  Considering that alveolar macrophage, DC, and 
monocyte populations decreased in response to U112 infection by day 3, it is plausible that 
there is a balance between macrophage recruitment to the lung and macrophage killing which 
would result in no net change from day 1 to day 3, though more experimental work is needed 
to determine if this is the case.  There was no difference between the number of interstitial 
macrophages in infected lungs and lungs from PBS control mice at day 1.   
In response to Francisella infection, there was a significant increase in the number of 
neutrophils in the lungs of mice infected by each strain from day 1 to day 3 (Figure 3.5F) 
indicating that infection resulted in neutrophil recruitment, but not until after at least 24 hours 
following exposure.  One day post-inhalation there was no increase in the number of 
neutrophils in the lungs of infected mice compared to PBS-inoculated control mice.  We 
consistently observed fewer neutrophils at day 1 in Schu S4-infected mice than PBS control 
mice (p<.05), suggesting that Schu S4 may initially suppress neutrophil recruitment more 
efficiently than U112 or LVS.   
Unlike other cell types analyzed, ATII cells are stationary structural cells.  As 
expected, there was no significant change in the number of ATII cells in response to 
Francisella infection by U112, LVS, or Schu S4 from day 1 to day 3 (Figure 3.5G), but these 
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studies do not address any effects that infection may have on ATII cell physiology or 
function.   
Taken together, these data demonstrate that the innate immune response to LVS and 
Schu S4 in the lung is similar despite differences in the lethal dose of each strain.  Upon 
inhalation, Francisella infects a variety of host cells, though alveolar macrophages are the 
predominant infected cell early during infection while neutrophils are recruited and become 
the main host cell in the later stages of pulmonary tularemia.  U112 differed from both LVS 
and Schu S4 in that it was taken up by neutrophils more rapidly following inhalation, and this 
apparently occurs without significant recruitment of new neutrophils to the lung.  U112 
infection also impacted macrophage, DC, and monocyte populations differently during the 
disease course than LVS or Schu S4. 
 
Discussion 
A goal of this study was to determine which cells in the lung become infected by F. 
tularensis following inhalation, and identify how these populations are altered during 
pulmonary tularemia.  At the same time, we sought to compare three commonly studied 
Francisella strains with regard to cell infection and impact on population dynamics in the 
lung.  Understanding the similarities and differences among strains will enable more accurate 
interpretations of other studies using these strains, as well as facilitate more specific inquiries 
into Francisella disease mechanisms.   
To directly compare lung infections of Francisella strains, we initiated infection with 
similar numbers of each strain.  Our dose range allowed detection of infected cell-types from 
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whole lung digests 24 hours post-inoculation.  Infected cells were not consistently 
distinguished from background at this time point from mice inoculated with less than 100 
bacteria.  However, mice similarly infected with 10 CFU of Schu S4 displayed a similar suite 
of infected cells and similar recruitment of monocytes and neutrophils at day 3 as mice 
inoculated with 300-400 CFU (data not shown) indicating that Francisella biology in the 
lung at a higher dose was not appreciably different than that of a very low dose.       
During the early stages of infection, LVS- and Schu S4-mediated disease appeared 
similar while U112 displayed fundamental differences.  The most common infected cell-type 
24 hours after inhalation of each strain was alveolar macrophages, although interstitial 
macrophages, CD11b
low/mid
 DCs, and ATII cells were also infected. In contrast, U112 was 
found in neutrophils at 24 hours but LVS and Schu S4 were not.  While there was no 
apparent influx of neutrophils overall at this stage of infection, there were almost 1000-fold 
more neutrophils associated with U112 than with LVS or Schu S4, indicating that neutrophils 
responded to and phagocytosed U112 to a significantly greater extent than LVS or Schu S4.  
Also, U112-infected mice lost alveolar macrophages, DCs, and monocytes during the 
course of disease, whereas depletion of these cell-types was not observed in LVS- or Schu 
S4-infected mice.  Potentially, phagocytes that are infected in the early stages of disease 
begin to undergo apoptosis or necrosis by day 3.  More studies are needed to determine if 
U112 infection results in more rapid killing of infected cells than infection by LVS or Schu 
S4. 
Other studies have noted differences in U112 when compared to LVS or Schu S4.  
For example, subspecies novicida exhibits different immuno-stimulatory properties in a 
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mammalian host than subspecies holarctica or tularensis.  U112 LPS stimulates 
macrophages to produce pro-inflammatory cytokines such as TNF-α, which are important in 
signaling the recruitment of neutrophils and monocytes, whereas LPS of LVS and Schu S4 
does not (21).  We therefore might have expected that U112 would provoke a more rapid or 
robust neutrophil influx than LVS or Schu S4, but this was not the case.  Though 
significantly more U112 organisms were observed in neutrophils early during infection than 
LVS or Schu S4, there was no difference in the abundance of neutrophils in U112-infected 
lungs than the other strains or PBS control mice.  A different study reported that inhalation of 
U112 did not lead to neutrophil recruitment in the lung by 24 hours (9), which is consistent 
with our observations.  In addition to neutrophil recruitment, we observed an increase in the 
number of monocytes in LVS- and Schu S4-infected mouse lungs, however the number of 
these cells in U112-infected mice decreased.  Different studies are needed to determine 
whether monocyte recruitment is being blocked by U112 or whether these cells are being 
killed at a more rapid rate than they are recruited.   
Francisella’s high capacity to cause disease in mammals is not entirely explained by 
lack of host-recognition.  Francisella-infected macrophages are unable to respond to pro-
inflammatory stimuli, such as E. coli LPS (25), indicating an active suppression of this 
response.  Though the complete mechanisms for inflammatory cytokine suppression is 
unclear, there is evidence that LVS and Schu S4 stimulate production of the immuno-
suppressive cytokine, TGF-β within infected pulmonary macrophages and DCs (3, 4).  TGF-
β leads to up-regulation of Fc-receptor on macrophages which increases the phagocytic 
capability of these cells (29), while at the same time limits production of IFNγ and other pro-
inflammatory molecules (13).  Normally, increased phagocytosis by macrophages would 
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expedite clearance of bacterial infection.  However, given Francisella’s ability to survive and 
replicate within these cells, this may exacerbate replication of the organism within the host.  
While production of TGF-β and other immuno-suppressive mediators may delay influx of 
inflammatory cells, this study demonstrates that eventual neutrophil and monocyte 
recruitment did occur in response to Francisella infection in the lung, however these cells 
contribute to disease progression by becoming host cells for Francisella replication.         
Normally, neutrophils are key to controlling bacterial infections with a significant 
intra-macrophage growth component (11).  Despite the evolution of neutrophils as efficient 
microbial killers, the data presented here demonstrate that interactions with neutrophils are a 
key component of Francisella pathogenesis within the lung.  Recent in vitro studies 
demonstrated that LVS is rapidly taken up by human neutrophils, but the respiratory burst is 
prevented due to disruption in NADPH oxidase assembly within the phagosome.  This 
process is apparently due to an undefined active bacterial process, as Francisella infection 
also prevented neutrophils from responding to potent heterologous stimuli (1, 16).  
Another observation from this study was that infected ATII cells, which are non-
migratory, were as abundant as infected DCs or interstitial macrophages during the early 
stages of disease.  Francisella interactions with ATII cells could play a unique role in 
pulmonary tularemia.  Cell-cell junctions of the epithelium and endothelium are affected by 
infection-induced cytokines and chemokines which facilitate chemotaxis of neutrophils and 
monocytes from the blood stream to infected tissue.  The alveolar epithelium is closely 
associated with blood vessels to provide efficient oxygen exchange, and in addition to 
facilitating inflammatory cell recruitment into the lung, increasing numbers of Francisella 
within ATII cells during disease progression could provide a method of bacterial entry into 
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the blood stream.  In this way, ATII cells could provide a “gateway” to the blood stream 
where bacteria could then disseminate to distal organs such as liver and spleen.  Further 
studies are ongoing in our lab to decipher the unique contribution of ATII cells during 
inhalation-acquired tularemia.   
 
Experimental Procedures 
Bacterial Culture 
Francisella strains were maintained on chocolate agar supplemented with Isovitalex 
(BD Biosciences).  U112 was a gift from Colin Manoil, LVS was obtained from the CDC in 
Atlanta GA, and Schu S4 from BEI Resources.  GFP strains contained a modified 
pKK214gfp plasmid (a kind gift from Mats Forsman). 
 
Mouse infections 
Female 7-10 week-old C57BL/6 mice were inoculated with Francisella strains 
diluted in sterile PBS and enumerated by Klett reading or OD600.  Dose was verified by 
plating inoculum on chocolate agar.  Mice were anesthetized with avertin until unresponsive 
to toe pinch, and 50 µL of bacterial suspension was dispensed onto nares of the mouse.  
Previous results suggest this is an effective procedure for establishing a pulmonary 
Francisella infection (10).  All animal experiments were
 
conducted in accordance with 
animal care and use guidelines,
 
and animal protocols were approved by the IACUC at UNC-
Chapel Hill. 
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Lung cell isolation 
Mice were anesthetized with avertin+heparin (1000 U/mL) and profused with 4-7 mL 
of PBS+heparin (200 U/mL).  Tracheas were cannulated using a 16-gauge blunt-tipped 
needle, and lungs were inflated with approximately 1 mL of dispase (BD Biosciences).  The 
trachea was tied off with surgical sutures and lungs were removed and incubated in 3.0 mL 
dispase at room temperature for 45 minutes.  Tracheas were removed, and lungs were 
transferred to a Petri plate along with 7 mL of PBS+DNaseI (250 µg/mL) and tissue was 
teased apart using forceps.  Cells were gently swirled for 1-2 minutes, and the suspension 
was filtered through 40 µm mesh.  Filtered suspensions were pelleted by centrifugation at 
300 x g for 5 minutes at 4
o
C and resuspended in 1 mL red blood cell lysis solution for 2 
minutes at room temperature before adding 9 mL PBS to neutralize osmolarity.  Cells were 
pelleted and resuspended in PBS and enumerated.   
 
Cell sorting and fluorescence microscopy       
Cell sorting was performed using a MoFlo (Dako) cell sorter, and collected cells were 
dispensed onto poly-L-lysine coated glass coverslips and allowed to adhere for 1 hour at 4
o
C.  
Cells were stained with DAPI mounting media and observed using a Zeiss Axioplan 2 
epifluorescence microscope and analyzed using SlideBook digital deconvolution software 
(Intelligent Imaging Innovation). 
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Staining of lung cells for flow cytometry 
Cells were kept on ice and all incubations were done at 4
o
C.  Lung cells were 
incubated in 24.G2 culture supernatant for 20 minutes to block Fc receptors.  10
6
 cells were 
stained with the following fluorescently-labeled antibodies to cell surface components, F4/80 
PE (clone BM8 - eBioscience), GR-1 PerCP (clone RB6-8C5 - BD Biosciences), CD11b PE-
Cy7 (clone M1/70 - eBioscience), and CD11c Alexa 647 (clone N418 - eBioscience) in flow 
buffer (1% BSA and .09% sodium azide in PBS) for 30 minutes.  Cells were washed with 
PBS and fixed with 4% paraformaldehyde (PFA) in PBS for 30 minutes.  Cells were washed 
and resuspended in PBS and stored at 4
o
C until analysis by flow cytometry. 
 
Intracellular staining for ATII cells 
The 3C9 antibody (Abcam), which is specific for LBM180 expressed in ATII cells 
(32), was labeled using a Alexa 647 Zenon mouse IgG2a antibody labeling kit (Invitrogen) 
according to manufacturers instructions.  Lung cells were incubated in clone 24.G2 culture 
supernatant for 20 minutes to block Fc receptors, fixed, and permeabilized with 
Cytofix/Cytoperm buffer (BD Biosciences) for 30 minutes and were washed with Cytoperm 
buffer (BD Biosciences).  Permeabilized cells were incubated with labeled 3C9 antibody in 
Cytoperm buffer for 30 minutes and washed with Cytoperm buffer before resuspending in 
PBS and stored at 4
o
C until analysis by flow cytometry. 
 
Flow cytometry of lung cells and data analysis 
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Cells were analyzed using a CyAn™ ADP LX 9 Color flow cytometer (Dako).  Data 
was analyzed using Summit v4.3 (Dako).  Compensation was performed using lung cells 
stained with each labeled antibody individually, and gates were drawn based on n-1 controls.  
Data bars represent the mean of 3-6 mice with error bars representing standard deviation of 
the mean.  Significance was determined using an unpaired two-tailed T-test assuming 
unequal variance.  P-values of <.05 were characterized as significant. 
 
Identifying Lung Cell Types 
Lung homogenates were treated with cell-type-specific fluorescently-labeled 
antibodies for the identification of cell populations (Figure 2, Table 1).  The cell type we 
have defined as alveolar macrophages have phenotypic characteristics of this cell-type (28).  
ATII cells were defined as highly expressing LBM180.  No LBM180 expressing cells were 
observed in splenocytes (data not shown) and >96% of LBM180 staining cells were GFP+ in 
an EGFP/SP-C transgenic mouse (data not shown) where GFP expression is driven by the 
SP-C promoter which is only active in ATII cells (20). 
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 U112 LVS Schu S4 
Subspecies 
Genome (19): 
     Size 
     G+C content 
     Predicted ORFs 
     Pseudogenes 
      
Sequence  
similarity                                                               
of common genes 
 
novicida 
 
1,910,031 bp 
32.47% 
1731 
14 
 
97.8% to LVS 
98.1% to Schu S4 
holarctica 
 
1,895,998 bp 
32.15% 
1380 
303 
 
97.8% to U112 
99.2% to Schu S4 
tularensis 
 
1,892,819 bp 
32.26% 
1445 
254 
 
98.1% to U112 
99.2% to LVS 
Intracellular 
replication: 
     Macrophages
a 
 
(2, 27) 
      
     ATII cells
a
  
(10) 
 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
Virulence in mice 
(inhalation)  
(8, 17) 
 
High Moderate High 
Virulence in 
humans
b 
 
(inhalation)  
(22, 26) 
 
None reported Low High 
Dissemination to 
distal organs post-
inhalation
a
  
(5, 8, 18) 
 
+ + + 
Lethal inhalation 
dose in mice
a
  
(7, 8) 
10-100 500-5000 < 10 
a - unpublished observations from our lab for all strains 
b - for immuno-competent adults 
 
Table 3.1. Comparison of Francisella tularensis strains 
64 
 
Cell Type Properties 
Alveolar Macrophage F4/80
high
, CD11b
low
, CD11c
high
, GR-1
low
, FS
high
,SS
high
 
Interstitial 
Macrophage 
F4/80
high
, CD11b
high
, CD11c
var
, GR-1
low
, FS
var
,SS
var
 
CD11b
low/mid
 DC F4/80
low
, CD11b
low/mid
, CD11c
high
, GR-1
low
, FS
mid
,SS
mid
 
CD11b
high 
DC F4/80
low
, CD11b
high
, CD11c
high
, GR-1
low
, FS
low/mid
,SS
low/mid
 
Monocyte F4/80
low
, CD11b
mid
, CD11c
low/mid
, GR-1
low/mid
, FS
low
,SS
low
 
Neutrophil F4/80
low
, CD11b
high
, CD11c
low
, GR-1
high
, FS
var
,SS
var
 
ATII Epithelial LBP18
high
, FS
mid
, SS
high
 , (low for other markers) 
Table 3.2.  Identification of specific cell-types from lung homogenates. 
  
65 
 
 
 
Figure 3.1.  Identifying Francisella-infected lung cells. Lung cells infected with GFP+ 
Francisella are readily detectable by flow cytometry.  Mice were intranasally inoculated with 
GFP+ Francisella strains and on days 1 and 3 post-inoculation, lungs were harvested and 
digested to produce a single cell suspension which could be further analyzed.  (A) GFP+ lung 
cells were detected on day 1 following intranasal inoculation with LVSgfp.  (B) GFP
high
, 
GFP
low
, and GFP
negative
 populations were collected and plated on coverslips for analysis by 
fluorescence microscopy.  (C) The absolute number of GFP+ lung cells from mice infected 
with U112, LVS, or Schu S4 was determined on day 1 and day 3 post-inoculation.  Error bars 
represent standard deviation of the mean (n=3-6 mice).  Statistical significance of differences 
between day 1 and day 3 was determined by unpaired two-tailed T-test assuming unequal 
variance (* p<.05). 
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Figure 3.2.  Identifying cell types in the lung by flow cytometry.Cell types were identified  
based on differential expression of F4/80, CD11b, CD11c, and GR-1.  Mouse lungs were 
digested with dispase and cells were stained with fluorescently-labeled cell-type-specific 
antibodies.  (A) F4/80+ cells (B) that were CD11b
low
 were classified as alveolar macrophages 
while F4/80
high
CD11b
high
 cells were classified as interstitial macrophages. (C) 
F4/80
low
CD11c
high
 cells were classified as DCs and subdivided into CD11b
low/mid
 DCs and 
CD11b
high 
DCs.  F4/80
low
CD11c
low
 CD11b
mid
 cells were classified as monocytes.  (D) 
F4/80
low
CD11c
low
 CD11b
high
GR-1
high
 cells were classified as neutrophils. 
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Figure 3.3. Lung cell types infected by Francisella following inhalation. Proportion of 
lung cell-types infected with Francisella strains U112, LVS, or Schu S4 on day 1 and day 3 
post-inoculation. 
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Figure 3.4.  Number of Francisella-infected cells following inhalation. Absolute number 
of infected (A) alveolar macrophages, (B) interstitial macrophages, (C) CD11b
low/mid
 DCs, 
(D) CD11b
high
 DCs, (E) monocytes, (F) neutrophils, and (G) ATII cells from mouse lungs on 
day1 and day 3 following intranasal inoculation with U112, LVS, or Schu S4.  Error bars 
represent standard deviation of the mean (n=3-6 mice).  Statistical significance of differences 
between day 1 and day 3 was determined by unpaired two-tailed T-test assuming unequal 
variance (* p<.05, ** p<.005, *** p<.0005). 
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Figure 3.5.  Effects of Francisella infection on cell number within lung populations. 
Absolute number of (A) alveolar macrophages, (B) interstitial macrophages, (C) CD11b
low/mid
 
DCs, (D) CD11b
high
 DCs, (E) monocytes, (F) neutrophils, and (G) ATII cells from mouse 
lungs on day1 and day 3 following intranasal inoculation with U112, LVS, or Schu S4.  Error 
bars represent standard deviation of the mean (n=3-6 mice).  Statistical significance of 
differences between day 1 and day 3 was determined by unpaired two-tailed T-test assuming 
unequal variance (* p<.05, ** p<.005, *** p<.0005). 
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Abstract 
 
Francisella tularensis, a gram-negative facultative intracellular bacterial pathogen, 
causes disseminating infections in humans and other mammalian hosts. Macrophages and 
other monocytes have long been considered the primary site of F. tularensis replication in 
infected animals. However, recently it was reported that F. tularensis also invades and 
replicates within alveolar epithelial cells following inhalation in a mouse model of tularemia. 
TC-1 cells, a mouse lung epithelial cell line, were used to study the process of F. tularensis 
invasion and intracellular trafficking within nonphagocytic cells. Live and paraformaldehyde 
fixed F. tularensis live vaccine strain (LVS) associated with, and were internalized by, TC-1 
cells at a similar frequency and with indistinguishable differences in kinetics. Inhibitors of 
microfilament and microtubule activity resulted in significantly decreased F. tularensis 
invasion, as did inhibitors of PI3 kinase and tyrosine kinase activity. Collectively these 
results suggest that F. tularensis epithelial cell invasion is mediated by a preformed ligand on 
the bacterial surface and driven entirely by host cell processes. Once internalized, F. 
74 
 
tularensis containing endosomes associated with EEA1 followed by LAMP-1 with peak co-
association frequencies occurring at 30 and 120 minutes post-inoculation, respectively. By 2 
hours post-inoculation 70.0% (±5.5%) of intracellular bacteria were accessible to antibody 
delivered to the cytoplasm indicating vacuolar breakdown and escape into the cytoplasm. 
 
Introduction 
Francisella tularensis, the causative agent of the disease tularemia, infects a wide 
range of animal hosts. Humans can be infected by a variety of routes, including physical 
contact with infected animals, insect bites, ingestion of contaminated food or water, and 
inhalation of organisms (13, 52). Disease severity is affected by both the route of inoculation 
and bacterial subtype (13, 48, 52). F. tularensis strains are subdivided into two groups, A and 
B; the more severe form of tularemia in humans is caused by type A strains (13, 48, 52). The 
type A strain F. tularensis subspecies tularensis is found almost exclusively in North 
America, whereas the type B strain F. tularensis subspecies holarctica is found throughout 
Europe, as well as in North America (35). There is a 5% to 15% mortality rate associated 
with untreated human tularemia caused by type A strains, however that rate reaches 30% to 
60% for untreated pneumonic and typhoid forms of the disease (11). The live vaccine strain 
(LVS) is an attenuated type B strain that causes a tularemia-like disease in mice, and is used 
as a model organism to study F. tularensis pathogenesis. There has been heightened interest 
in the study of this organism in recent years due to its history of weaponization and potential 
for use as an agent of biological warfare. F. tularensis is a category A select agent on the 
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CDC's bioterrorism agent list, which includes organisms with the potential to cause high 
numbers of casualties if disseminated in an aerosol form (26). 
Much of the Francisella pathogenesis research has focused on survival and 
replication of F. tularensis in macrophages and dendritic cells, and many of the genes 
identified to date that are required for full virulence contribute to survival or replication in 
the macrophage (1, 6, 17, 20, 27, 30, 32, 37, 42). We recently demonstrated that F. tularensis 
also invades and replicates in alveolar type II (ATII) epithelial cells of infected mice (21). 
ATII cells have a number of biological functions, including the production, secretion and 
recycling of surfactant, proliferation to produce additional type II cells as well as 
transdifferentiation into type I cells, maintenance of alveolar fluid balance, and production of 
antimicrobial and anti-inflammatory substances(29). Due to the close proximity between the 
blood and alveolar epithelial cells required for gas exchange and fluid balance, these cells are 
ideally located to provide a portal through which bacteria could disseminate to distal organs. 
F. tularensis attaches to and invades nonphagocytic cells, including the ATII cell 
lines A549 and MLE 12 and the lung epithelial cell line TC-1 (21, 28).  Melillo et al. also 
reported that E. coli expressing the F. tularensis surface protein FsaP bind to A549 cells (31), 
identifying a surface protein that may play a role in ATII cell association. 
A primary function of monocytes is to engulf bacterial cells and other foreign 
particles (24, 44). However, invasion of epithelial and other nonphagocytic host tissue cells 
requires bacterially mediated exploitation of host cell functions to gain entry (10, 15, 16). 
Alveolar epithelial cells provide a site where F. tularensis can replicate in the infected host 
(21), and as such it is important to understand how bacterial interaction with these cells may 
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differ from interaction with macrophages. Herein we describe our efforts to understand how 
F. tularensis invades lung epithelial cells. 
 
Materials and Methods 
Bacterial strains 
Francisella tularensis LVS was obtained from the Centers for Disease Control and 
Prevention, Atlanta, Ga. LVSgfp was constructed using the pKK214GFP plasmid (a gift of 
Mats Forsman). F. tularensis LVS and LVSgfp were propagated on chocolate agar 
supplemented with 1% IsoVitaleX (Becton-Dickinson). Listeria monocytogenes EGD1/2a, 
Salmonella enterica serovar Typhimurium, Yersinia pseudotuberculosis, and Campylobacter 
jejuni strain 81-176 were gifts from Paul Orndorff, Craig Altier, Ralph Isberg, and Deborah 
Threadgill, respectively. All bacterial strains were grown on LB agar, with the exception of 
C. jejuni, which was grown on Mueller-Hinton agar with 5% CO2, and F. tularensis LVS, 
which was grown on chocolate agar as described above. All bacterial strains were grown at 
37°C. Salmonella enterica was grown overnight in LB broth under static conditions for 
invasion assays. 
 
Cell culture 
TC-1 (ATCC CRL-2785) is a tumor cell line derived from primary lung epithelial 
cells of C57BL/6 mice. The cells were immortalized with HPV-16 E6
 
and E7 and 
transformed with the c-H-ras oncogene. These cells were grown in RPMI 1640 
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supplemented with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 10 mM HEPES, 1.0 mM 
sodium pyruvate, 0.1 mM non-essential amino acids and 10% FBS. Cell cultures were 
maintained at 37°C and 5% CO2. 
 
Attachment, Invasion and Vacuolar Escape Assay 
To evaluate the percentage of TC-1 cells with associated bacteria synchronized 
infections were carried out by adding F. tularensis LVS expressing GFP (LVSgfp) at a 
multiplicity of infection (MOI) of 100 to TC-1 cells chilled to 4°C. Bacterial suspensions 
were made in tissue culture media from bacteria grown as described above. Bacterial 
concentration of suspensions was determined using a Klett meter.  Dilutions of suspensions 
were plated to verify MOI. Plates were centrifuged at 300 x g for 5 minutes at 4°C, and then 
rapidly warmed by placing in a 37°C water bath for 2 minutes before transferring to a 37°C, 
5% CO2 incubator. For experiments using killed LVS, organisms were treated with 4% 
paraformaldehyde (PFA) for 10 minutes. There was no growth from a PFA treated bacterial 
aliquot that was plated on chocolate agar, demonstrating that PFA treatment killed all 
organisms. At 10 minutes post-inoculation samples were washed with PBS to remove 
unattached bacteria and pre-warmed media was added to monolayers. Cells were collected by 
trypsinization at 10, 20, 30 and 60 minutes post-inoculation and samples were processed at 
4°C. Cells to be analyzed for bacteria association were fixed in 4% PFA for 10 minutes, and 
analyzed by flow cytometry. 
Parallel wells were analyzed for intracellular bacteria by collecting samples as 
described above. Extracellular bacteria were labeled using anti-F. tularensis LPS antibody 
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(USBiological) conjugated to Pacific Blue (Molecular Probes) 1:1000 for 30 minutes at 4°C. 
Cells were then lysed with water and centrifuged at 300 x g to removed eukaryotic cell 
debris. Supernatant containing bacteria was centrifuged at 16,000 x g, fixed with 4% PFA, 
and analyzed by flow cytometry to differentiate intracellular (GFP only) from extracellular 
(GFP and Pacific Blue) bacteria. 
To evaluate bacterial escape into the cytoplasm, synchronized inoculations of TC-1 
cells and staining of extracellular bacteria was done as described above. Cells were collected 
by trypsinization at 10, 20, 30, 60 and 120 minutes post-inoculation. TC-1 cells were treated 
with 50 g/ml digitonin in KHM buffer (110 mM potassium acetate/20 mM Hepes/2 mM 
MgCl2, pH 7.3) for 1 minute, washed in KHM buffer, and incubated with anti-F. tularensis 
LPS antibody conjugated to Alexa Fluor 647 (Molecular Probes) 1:1000 for 30 minutes at 
4°C. Cells were then washed in KHM buffer, lysed with water and centrifuged at 300 x g to 
removed cellular debris. Supernatants were centrifuged at 16,000 x g and bacterial pellets 
were fixed in 4% PFA and analyzed by flow cytometry to differentiate extracellular (GFP, 
Pacific Blue and Alexa Fluor 647), cytoplasmic (GFP and Alexa Fluor 647) and vacuolar 
(GFP only) bacteria. 
Flow cytometry of whole cells and bacteria was performed using a CyAn ADP flow 
cytometer (Dako Cytomation). Data was analyzed using Summit Software (Dako), with 
gating for single events for whole cell samples and GFP positive single events for bacterial 
samples.  
 
Inhibitor Assays 
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Inhibitor assays were carried out with cytochalasin D, colchicine, wortmannin and 
genistein. Cytochalasin D, an actin polymerization inhibitor, was used at 0.5 and 1.0 µM 
concentrations. Colchicine, a microtubule polymerization inhibitor, was used at 0.1 and 0.25 
µM concentrations. Wortmannin, an inhibitor of PI3 kinase activity, was used at 100 and 200 
nM concentrations. Genistein, an inhibitor of tyrosine kinase activity, was used at 50 and 100 
µM concentrations. Monolayers were preincubated for one hour with escalating 
concentrations of inhibitor, and then bacteria suspended in media containing inhibitor were 
added at an MOI of 100 for LVS, or 25 to 50 for other bacteria. Samples without inhibitor 
included bacteria suspended in tissue culture media alone, or media containing the carrier in 
which the inhibitor was reconstituted where appropriate. After four hours, cells were washed 
with PBS to remove inhibitor. Extracellular bacteria were killed by adding media containing 
25 g/ml of gentamicin and incubated 2 hours before monolayers were washed with PBS and 
scraped from the plate using sterile applicator sticks. Serial dilutions were plated on 
chocolate agar to quantify colony forming units (CFU) of intracellular bacteria. Inhibitors did 
not affect LVS viability as demonstrated by incubating bacteria in tissue culture media 
containing inhibitor for four hours, followed by plating onto chocolate agar to quantify CFU. 
Inhibitors did not affect eukaryotic cell viability at the concentrations used as determined by 
Trypan Blue exclusion. The effect of inhibitors on bacterial attachment to cells was 
determined as described above for invasion, except that gentamicin was not added, allowing 
bacteria attached to cells but not internalized to be included in the CFU recovered. Inhibitors 
had no effect on LVS attachment to TC-1 cells. Results are expressed as the percentage of 
LVS or control organism that survived gentamicin treatment, relative to the sample without 
inhibitor inoculated with the same organism. Invasion without inhibitor is defined as 100% 
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invasion. Data presented are the results of assays done in triplicate, and are representative of 
multiple repetitions of each experiment. Data were analyzed for statistical significance by 
paired two-tailed t test, and considered significantly different from the untreated control 
when P<0.01. 
 
Fluorescence microscopy 
Cells were grown on poly-L-lysine coated coverslips in 24-well cell culture plates to 
~90% confluency.  LVSgfp was added at an MOI of 100 to pre-chilled TC-1 plates, and 
centrifuged at 300 x g for three minutes to synchronize infection as described above. At 10, 
20, 30, 60, 120 and 180 minutes post-inoculation monolayers were washed with PBS to 
remove unattached bacteria and fixed using 4% PFA. Samples were blocked with PBS/Fc 
block/5% donkey serum, incubated with anti-F. tularensis LPS diluted 1:1000 for 30 minutes 
at 4°C followed by donkey anti-mouse AMCA (7-amino-4-methylcoumarin-3-acetic acid, 
Jackson ImmuoResearch) diluted 1:100, 30 minutes, 4°C to label extracellular bacteria. For 
early endosome antigen 1 (EEA1) or lysosome associated membrane protein 1 (LAMP-1) 
staining samples were blocked using PBS/0.1% saponin/5% serum of host species of 
secondary antibody followed by goat polyclonal anti-EEA1 (N-19; Santa Cruz 
Biotechnologies) diluted 1:200 in blocking solution, or rat monoclonal anti-mouse LAMP-1 
(1D4B, developed by J. T. August, obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD and maintained by The University of 
Iowa, Department of Biological Sciences, Iowa City, IA 52242) diluted 1:200 in blocking 
solution. Secondary antibodies used were donkey anti-goat Cy5 (Jackson ImmunoResearch) 
or goat anti-rat Alexa Fluor 647 (Molecular Probes), diluted 1:500 in PBS/0.1% saponin. 
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Samples were examined using a Zeiss Axioplan 2 epifluorescence microscope and SlideBook 
digital deconvolution software (Intelligent Imaging Innovations). 100 intracellular bacteria 
were counted for each time point and condition. Images of sequential vertical planes were 
acquired to determine the location of bacteria within EEA1 or LAMP-1 containing vacuoles. 
Data presented are the results of three independent experiments.  
 
Electron microscopy 
Cell monolayers grown on polystyrene plates were rinsed with PBS or serum-free 
medium and fixed in 3% glutaraldehyde/0.15M sodium phosphate, pH 7.4. Following three 
rinses with sodium phosphate buffer, the monolayers were post-fixed for 1 hour in 1% 
osmium tetroxide/1.25% potassium ferrocyanide/0.15M sodium phosphate buffer,  rinsed in 
deionized water, dehydrated using increasing concentrations of ethanol (30%, 50%, 75%, 
100%, 100%, 10 minutes each) and embedded in Polybed 812 epoxy resin (Polysciences, 
Inc.,Warrington, PA).   The embedded samples were sectioned parallel and perpendicular to 
the substrate at 70nm using a diamond knife.  Ultrathin sections were collected on 200 mesh 
copper grids and stained with 4% aqueous uranyl acetate for 15 minutes, followed by 
Reynolds’ lead citrate for 7 minutes.  Sections were observed using a LEO EM910 
transmission electron microscope at 80kV (LEO Electron Microscopy, Thornwood, NY) and 
photographed using a Gatan Bioscan Digital Camera (Gatan, Inc., Pleasanton, CA). 
 
Results 
Kinetics of F. tularensis epithelial cell attachment and invasion 
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Francisella tularensis LVS invades and replicates within TC-1, MLE 12 and A549 
lung epithelial cell lines (21). While the intracellular replication rates within these lines are 
indistinguishable, TC-1 cells support the highest initial invasion frequency (21).  In addition, 
TC-1 cells are a mouse cell line, and LVS infection causes a tularemia-like disease in mice 
similar to that seen with virulent strains in humans. We therefore used TC-1 cells to examine 
the initial stages of F. tularensis invasion. 
To determine kinetics of lung cell attachment and invasion by F. tularensis we 
synchronized infection of TC-1 cells at an MOI of 100 with LVSgfp. At 10, 20, 30 and 60 
minutes post-inoculation, cells were washed to remove nonadherent bacteria and collected to 
quantify TC-1 cells associated with GFP expressing bacteria by flow cytometry (Figure 
4.1A). At these same time points, in parallel samples, extracellular bacteria were stained 
using a Pacific Blue labeled antibody to F. tularensis LPS and TC-1 cells were lysed to 
recover cell-associated bacteria. GFP positive bacteria recovered from cells were analyzed by 
flow cytometry to determine intracellular (GFP alone) versus extracellular (GFP and Pacific 
Blue) localization (Figure 4.1B). At 10 minutes 1.7% (±0.4%) of TC-1 cells had associated 
bacteria, of which 1.4% (±0.1%) of TC-1 cell-associated bacteria were intracellular. At 20 
minutes post-inoculation 1.1% (±0.2%) of TC-1 cells had cell-associated bacteria, of which 
7.0% (±0.6%) were internal. At 30 minutes post-inoculation 1.0% (±0.2%) of TC-1 cells had 
cell-associated bacteria, of which 21.3% (±6.3%) were internal. At 60 minutes post-
inoculation 1.4% (±0.1%) of TC-1 cells had cell-associated bacteria, of which 23.6% 
(±5.8%) were intracellular.  
To determine if LVS entry into lung epithelial cells required viable bacteria, we 
repeated the above experiments using killed LVSgfp. At 10 minutes 0.9% (±0.2%) of TC-1 
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cells had dead bacteria associated with them, of which 1.2% (±0.4%) of TC-1 cell-associated 
bacteria were intracellular. At 20 minutes post-inoculation 1.1% (±0.7%) of TC-1cells had 
cell-associated dead bacteria, of which 5.7% (±0.6%) were internal. At 30 minutes post-
inoculation 0.6% (±0.2%) of TC-1 cells had cell-associated dead bacteria, of which 17.3% 
(±3.5%) were internal. At 60 minutes post-inoculation 0.4% (±0.1%) of cells had dead 
bacteria associated with them, of which 25.7% (±1.6%) were intracellular. These results 
indicated that both live and dead LVS attached to and invaded lung epithelial cells. Further, 
invasion frequency and kinetics were not significantly different between live and dead 
bacteria (P<0.01), except cell association at 60 minutes (Figure 4.1). The ability of nonviable 
F. tularensis to invade lung epithelial cells suggested that a preformed ligand on the bacterial 
surface may interact with the host cell. 
 
Effects of cytoskeleton and signaling pathway inhibitors on F. tularensis invasion of 
epithelial cells. 
Inhibitors of eukaryotic cell function were used to determine the contribution of host 
cell signaling and cytoskeleton rearrangement to LVS invasion of lung epithelial cells. 
Bacterial entry into host cells generally requires rearrangement of cytoskeletal structures; 
either microfilaments alone, as is the case with Salmonella, Shigella, Listeria and Yersinia 
spp. (12), or both microfilaments and microtubules, as is the case with Neisseria 
gonorrhoeae and Campylobacter jejuni (4, 43). 
To determine the contribution of actin polymerization to LVS invasion we incubated 
TC-1 lung epithelial cells with cytochalasin D, an actin polymerization inhibitor that disrupts 
microfilaments, and measured bacterial internalization by gentamicin protection assay. 
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Treatment of TC-1 cells with 0.5 and 1.0 μM cytochalasin D decreased LVS invasion more 
than 99% (±0.1%) (Figure 4.2A), whereas Salmonella enterica invasion, which is known to 
be actin dependent (36), decreased by 84.6% (±2.3%) and 88.1% (±2.5%) at the same 
inhibitor concentrations, respectively. TC-1 cell invasion by Campylobacter jejuni strain 81-
176, a strain which does not require actin for invasion of intestinal epithelial cells (34), was 
not decreased by actin inhibition.  
Microtubules are responsible for the cytoplasmic organization of eukaryotic cells, 
control of organelle transport, and are a primary component of cilia and flagella (55). 
Microtubule polymerization has been shown to contribute to the epithelial cell invasion of 
Neisseria gonorrhoeae and Campylobacter jejuni (4, 43). To determine the contribution of 
microtubules to LVS invasion we treated lung epithelial cells with colchicine, which binds 
tubulin and inhibits microtubule polymerization, and determined invasion by gentamicin 
protection assay. Treatment of TC-1 cells with colchicine decreased LVS invasion by 55.2% 
(±18.3%) and 94.2% (±2.4%) at 0.1 and 0.25 μM concentrations, respectively (Figure 4.2B). 
TC-1 cell invasion by Campylobacter jejuni strain 81-176, a strain for which invasion is 
blocked by microtubule depolymerization in intestinal epithelial cells (34), was decreased 
significantly at the higher colchicine concentration.  Salmonella enterica invasion, which is 
not considered microtubule dependent (4), did not demonstrate a statistically significant 
decrease in invasion at these concentrations.  
Signaling pathways are frequently manipulated by bacteria to cause the cytoskeletal 
rearrangement necessary to gain entry into nonphagocytic cells (10, 15, 16). PI3 kinase and 
tyrosine kinase signaling are exploited by other pathogens for invasion (25, 45). These 
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pathways were examined for their contribution to Francisella tularensis entry into lung 
epithelial cells.  
PI3 kinases phosphorylate inositol phospholipids, forming lipid products that are in 
turn involved in cellular functions such as cell growth, actin rearrangement and vesicular 
trafficking (51). To determine the importance of PI3 kinase signaling to F. tularensis 
invasion, lung epithelial cells were treated with wortmannin, an inhibitor of PI3 kinase 
activity, and invasion was assessed by gentamicin protection assay. Wortmannin decreased 
LVS invasion of TC-1 cells by 69.4% (±4.6%) and 84.1% (±1.8%) when cells were exposed 
to 100 and 200 nM concentrations, respectively (Figure 4.3A). Invasion by Listeria 
monocytogenes, which is PI3 kinase dependent (25), was significantly decreased. Salmonella 
enterica invasion, which is not PI3 kinase dependent (49), was not significantly decreased at 
these concentrations in TC-1 cells. 
Cells monitor and respond to their external environment via receptors that lead to 
intracellular signaling events (53). Activation of receptor tyrosine kinases can lead to 
receptor internalization, as well as initiation of a cascade of downstream signaling events 
(53). Some organisms, such as Yersinia pseudotuberculosis, exploit signaling through host 
cell receptors to gain entry into cells, and this entry can be blocked by tyrosine kinase 
inhibitors (45). To determine the contribution of tyrosine kinase signaling to LVS invasion, 
the inhibitor genistein was added to lung epithelial cells and the number of intracellular 
organisms measured by gentamicin protection assay. Genistein decreased LVS invasion of 
TC-1 cells by 68.1% (±1.1%) and 77.1% (±1.1%) at 50 and 100 μM concentrations, 
respectively (Figure 4.3B). Invasion by Yersinia pseudotuberculosis was significantly 
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reduced at these concentrations, while Salmonella enterica invasion, which is tyrosine kinase 
independent (45), was not significantly decreased in TC-1 cells. 
Collectively, these results indicate that actin and microtubule rearrangement both 
contribute to the entry of F. tularensis into lung epithelial cells. PI3 kinase and tyrosine 
kinase, proteins which regulate cytoskeletal rearrangement, both impact F. tularensis 
invasion of lung epithelial cells. 
 
LVS traffics along the endocytic pathway in lung epithelial cells 
To characterize the trafficking of F. tularensis LVS along the endocytic pathway in 
lung epithelial cells, we synchronized the addition of LVSgfp to TC-1 cells and evaluated 
these cells microscopically for the presence of bacteria inside vacuoles containing the early 
endosomal marker EEA1 or the late endosomal/lysosomal marker LAMP-1 (Figure 4.4A and 
4.4B). LVS association with EEA1 containing phagosomes increased from 1.4% (±2.4%) at 
10 minutes to 40.4% (±5.3%) at 30 minutes, before decreasing (Figure 4.4C). LVS 
association with LAMP-1 containing vacuoles peaked two hours post-inoculation at 49.3% 
(±3.5%) (Figure 4.4C). These results indicate that LVS traffics along the endocytic pathway 
in lung epithelial cells, associating first with early endosomes before progressing to late 
endosomes/lysosomes. 
 
LVS escapes the phagosome and replicates in the cytoplasm of lung epithelial cells 
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Once inside host cells invasive bacteria either replicate within the endosome or 
escape the vacuole and replicate in the cytoplasm. To determine the intracellular location of 
bacteria, TC-1 cells were inoculated with LVS at an MOI of 100 and examined at one and 24 
hours by transmission electron microscopy. At 1 hour post-inoculation LVS were TC-1 cells 
in a membrane-bound vacuole (Figure 4.5A). The membrane was easily visualized, and in 
some cases was beginning to degrade (Figure 4.5A). By 24 hours all observed intracellular 
bacteria were no longer contained within a visible membrane, and appeared to be free in the 
cytoplasm (Figure 4.5B), though they were surrounded by an electron lucent zone that has 
been noted by other researchers (8, 19). 
To determine the kinetics of LVS escape from the endocytic pathway into the 
cytoplasm of lung epithelial cells, we differentially labeled extracellular, cytoplasmic and 
vacuolar LVSgfp and analyzed recovered bacteria by flow cytometry (modified from 
Checroun et al.).We first labeled bacteria that were extracellular and attached to TC-1 cells 
using Pacific Blue conjugated anti-F. tularensis LPS. We then permeabilized the cytoplasic 
membrane of TC-1 cells using digitonin, allowing Alexa Fluor 647 conjugated anti-F. 
tularensis LPS to access cytoplasmic bacteria, but not those enclosed in intact vacuoles, 
which are digitonin impermeable. TC-1 cells were lysed and cell-associated bacteria 
recovered and analyzed by flow cytometry, gating on GFP to differentiate bacteria from 
residual TC-1 debris. The resulting three populations of bacteria were analyzed: extracellular 
(Pacific Blue, Alexa Fluor 647 and GFP), cytoplasmic (Alexa Fluor 647 and GFP), and 
vacuolar (GFP only) (Figure 4.6A and 4.6B). At 10 minutes post-inoculation 19.3% (±8.1%) 
of intracellular bacteria were accessible to antibody delivered to the cytoplasm, and therefore 
considered cytoplasmic (Figure 4.6C). This number increased to 70.0% (±5.5%) at 2 hours 
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post-inoculation, indicating that the majority of intracellular bacteria were no longer 
contained within intact endocytic vacuoles. It should be noted that once the vacuolar 
membrane begins to degrade bacteria are accessible to antibody. As a result, bacteria that 
were associated with LAMP-1 staining vacuoles at 2 hours post-inoculation (Figure 4.4C) 
would be identified as cytoplasmic by this assay if the vacuolar membrane was no longer 
intact. When TC-1 cells were treated with saponin, which permeabilizes both vacuolar and 
cytoplasmic membranes, greater than 99% of bacteria were accessible to antibody labeling 
(data not shown), demonstrating that a population of bacteria were protected from staining 
when only the cytoplasmic membrane was permeabilized. Microscopic examination of 
saponin treated TC-1 cells revealed that anti-F. tularensis antibody was able to access 
bacteria in EEA1 containing vacuoles, while antibody was excluded from these vacuoles in 
digitonin treated cells (data not shown). When TC-1 cells were inoculated with PFA killed 
bacteria >90% of organisms were vacuolar at 60 minutes post-inoculation, indicating that 
killed bacteria did not escape into the cytoplasm (data not shown). Thus, bacterial viability 
was required for escape from the epithelial cell endosome.  
 
Discussion 
The ability of many facultative intracellular bacterial pathogens to cause disease is 
dependent upon their ability to invade and replicate within various host cells (14, 22, 41). F. 
tularensis survival and replication within macrophages and dendritic cells has been well 
described (1, 5, 6, 8, 33). We previously demonstrated that F. tularensis LVS also localizes 
to and replicates within alveolar type II epithelial cells following inhalation of organisms in a 
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mouse model of infection (21), prompting us to investigate lung epithelial cell invasion by 
this organism. 
Alveolar type II cells account for about 12% of the total cells, and 2% of the surface 
area, of the alveolar region in mice (50). Approximately 98% of the surface area, and 10% of 
the total cell number, is comprised of type I cells, which provide structure and are the site of 
gas exchange (50). Type II cells have a number of biological functions, including the 
production, secretion and recycling of surfactant, proliferation to produce additional type II 
cells as well as transdifferentiation into type I cells, maintenance of alveolar fluid balance, 
and production of antimicrobial and anti-inflammatory substances (29). Due to the close 
proximity between the blood and alveolar epithelial cells required for gas exchange and fluid 
balance, these cells are ideally located to provide a portal through which bacteria could 
disseminate to distal organs.  
To characterize the interactions of F. tularensis with lung epithelial cells we 
investigated the initial interactions of LVS with the lung epithelial cell line TC-1. We 
determined that bacteria associated with and were internalized by lung epithelial cells within 
10 minutes of inoculation, and that viable bacteria were not necessary for gaining entry into 
these cells. We previously found that the frequency with which F. tularensis invaded lung 
epithelial cell lines was low (21). The low invasion frequency may be due to the inherent 
inability of a transformed cell line grown in a non-polarized fashion to recapitulate the 
complex environment within the host lung. These cells may also intermittently express a 
relevant receptor or other process that facilitates F. tularensis invasion in vivo. A system 
using primary cells grown in a polarized manner may more realistically reproduce the 
environment in the lung (18). Given the quantity of cells required for studies, cell culture 
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lines provide a reasonable place to begin the investigation of the interaction of bacteria with 
epithelial cells, and have been described as a model for such interactions (28). 
Pathogens have developed numerous means of exploiting host cell functions to gain 
entry into nonphagocytic cells (10, 15). These invasion strategies are typically classified as 
either a zipper mechanism, which is utilized by pathogens such as Yersinia 
pseudotuberculosis and Listeria monocytogenes or a trigger mechanism, which is utilized by 
organisms such as Salmonella typhimurium and Shigella flexneri. The zipper mechanism is 
characterized by bacterial surface proteins binding to host cell receptors leading to 
internalization. The trigger mechanism is characterized by the injection of bacterial effector 
proteins into the host cell via a type III secretion system resulting in bacterial engulfment via 
induced macropinocytosis. Entry by either of these mechanisms requires the manipulation of 
host cell cytoskeletal components and signaling pathways. A number of host cell receptors 
play a role in F. tularensis entry into macrophages, including Fcγ, CR3,  MR and SRA 
receptors (3, 38, 47). However, very little is known about how this organism is able to access 
cells that are not considered to be professional phagocytes.  
To better understand the process of F. tularensis entry into lung epithelial cells we 
investigated cytoskeletal components and signaling pathways that are involved in epithelial 
invasion by other bacterial pathogens for their contribution to internalization of LVS by a 
lung epithelial cell line. Lindemann et al. previously demonstrated that actin and 
microtubules are necessary for F. tularensis invasion the human epithelial cell line HEp-2 
(28). We determined that both actin and microtubules contribute to F. tularensis invasion of 
lung epithelial cells, as do PI3 kinases and tyrosine kinases, both of which can control 
signaling events leading to cytoskeletal rearrangement. We showed that F. tularensis 
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internalization by lung epithelial cells is dependent upon a variety of host cell mechanisms, 
and that interruption of any of these mechanisms interferes with bacterial invasion.  
We were unable to identify the characteristic membrane ruffling that is seen with 
Salmonella invasion either by phalloidin staining or Field Emission Scanning Electron 
Microscopy (FESEM) under conditions where we were able to clearly identify membrane 
ruffling with Salmonella (data not shown). While this points toward F.tularensis not causing 
massive actin reorganization at the site of entry it is possible that membrane ruffling occurs 
but was not detected by us. Listeria monocytogenes, another organism that is able to invade 
epithelial cells, also requires PI3 kinase and tyrosine kinase function for invasion, in a cell 
type dependent manner (39, 40). This organism has two invasion proteins, InlA and InlB, 
which interact with different host receptors, leading to different signaling events. It is 
possible that F. tularensis also uses multiple receptors for entry into lung epithelial cells, and 
that interruption of various signaling pathways could decrease uptake via various receptors. 
Toll-like receptors (TLRs) may play a role in modulation of the immune response to F. 
tularensis (9, 23, 54), and functional TLRs are present on ATII cells (2). However, TLRs 
have not been implicated among macrophage receptors for F. tularensis internalization 
identified to date, which include Fcγ, CR3,  MR and SRA receptors (3, 38, 47). Melillo et al. 
have reported that E. coli expressing the F. tularensis surface protein FsaP were able to bind 
A549 cells (31). We have also demonstrated that killed F. tularensis was taken up by lung 
epithelial cells. This information, taken together with the absence of genes predicted to 
encode a type III secretion system, point toward the presence of a preformed ligand receptor 
interaction as with the zipper mechanism of uptake, rather than injection into the host cell of 
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effector proteins as with organisms that gain entry via the trigger mechanism. Further studies 
are needed to identify receptors necessary for uptake of F. tularensis by nonphagocytic cells. 
 
To investigate F. tularensis trafficking along the endocytic pathway in lung epithelial 
cells we examined association of LVS with EEA1 and LAMP-1 containing vacuoles, as well 
as escape into the cytoplasm. F. tularensis traffics along the endocytic pathway in 
macrophages before escaping to the cytoplasm where replication occurs. The timing of this 
escape seems to be dependent upon the Francisella species and host cell type tested. F. 
tularensis subsp.novicida begins to disrupt the phagosomal membrane of quiescent human 
macrophages at 4 hours and is free in the cytoplasm by 12 hours post-infection (46). LVS 
and clinical isolates of  F. tularensis associate with EEA1 then LAMP-1 containing vacuoles 
in mouse bone marrow derived macrophages, human macrophages, and mouse and human 
macrophage-like cell lines before degrading the phagosomal membrane and beginning  to 
escape into the cytoplasm between one and two hours post-inoculation (7, 8, 19).  We 
determined that LVS was initially associated with EEA1 containing vacuoles, then LAMP-1 
containing vacuoles, before being found free in the cytoplasm of lung epithelial cells, in a 
manner and kinetic consistent with that seen in macrophages. 
F. tularensis LVS is found in ATII cells in the lungs of C57BL/6 mice 1, 3 and 7 days 
post-intranasal inoculation, replicates in these cells as disease progresses, and by day 7 
organisms are widespread in the alveolar epithelium (21).  These observations demonstrate 
that that ATII cell invasion and replication is a part of the F. tularensis disease process. 
Understanding how this bacterium gains access to these cells, and just as importantly, how 
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they replicate and establish a stronghold in the lung epithelium, is necessary to understanding 
the progression of respiratory tularemia, as well as potentially providing insight into methods 
that may be used to block bacterial uptake or replication, and thus prevent disease. 
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Figure 4.1. F. tularensis LVS association with and internalization by TC-1 lung epithelial 
cells. (A) Percent of TC-1 cells with associated live (♦) or PFA-fixed (■) LVS at designated 
times post-inoculation. * Data are significantly different from untreated control, P<0.01 by 
paired two-tailed t test. (B) Percent of TC-1 cell-associated live (♦) or PFA-fixed (■) LVS 
that are intracellular at designated times post-inoculation. 
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Figure 4.2. The effect of actin and microtubule polymerization on F. tularensis LVS 
invasion of lung epithelial cells. TC-1 cells were treated with designated concentrations of 
(A) cytochalasin D or (B) colchicine. Results are expressed as the percentage of LVS, 
Salmonella or Campylobacter that survived gentamicin treatment, relative to the sample 
without inhibitor inoculated with the same organism (defined as 100% invasion). * Data are 
significantly different from untreated control, P<0.01 by paired two-tailed t test. 
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Figure 4.3. The effect of PI3 kinase and tyrosine kinase activity on LVS invasion of lung 
epithelial cells. (A) Wortmannin or (B) genistein were added to TC-1 cells at the indicated 
concentrations. Results are expressed as the percentage of LVS or control organism that 
survived gentamicin treatment, relative to the sample without inhibitor inoculated with the 
same organism(defined as 100% invasion). * Data are significantly different from untreated 
control, P<0.01 by paired two-tailed t test 
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Figure 4.4. Representative fluorescence microscopy images demonstrating LVSgfp 
localization within EEA1 or LAMP-1containing endosomes in TC-1 cells. Images depict (A) 
TC-1 cells stained for EEA1 30 minutes post-inoculation with LVSgfp or (B) 2 hours post-
inoculation stained for LAMP-1. Single color images: LVSgfp images depict bacteria alone, 
EEA1 and LAMP-1 images depict staining for EEA1 or LAMP-1 only, and extracellular 
images depict staining of extracellular bacteria (no extracellular bacteria were present in B). 
The merged color images depict LVSgfp (green), vacuoles labeled with anti-EEA1 antibody 
(N19)(red) or anti-LAMP-1 (1D4B) (red), or extracellular LVS labeled with anti-F. 
tularensis LPS antibody conjugated to Pacific Blue (blue). Extracellular LVSgfp (arrow with 
round end), intracellular but not EEA1 associated LVSgfp (small arrow), and LVS associated 
with EEA1 containing vacuoles (large arrowhead). (C)Trafficking of LVSgfp in TC-1 cells. 
100 intracellular bacteria were counted for each condition and scored for association with 
EEA1 (♦) or LAMP-1 (▪) containing vacuoles. Three replicates were examined for each time 
point and condition. 
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Figure 4.5. Transmission electron micrographs of TC-1 infected with F. tularensis LVS. (A) 
One hour post-inoculation TC-1 cells showing LVS in a membrane bound vacuole that in 
some cases appeared to be degrading (arrow). (B) 24 hours post-inoculation LVS were free 
in the cytoplasm. 
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Figure 4.6. LVSgfp was analyzed by flow cytometry for escape from vacuoles into the 
cytoplasm of TC-1 cells. Extracellular bacteria were labeled with anti-F. tularensis LPS 
antibody conjugated to Pacific Blue (region R8). Cytoplasmic bacteria were identified by 
labeling with anti-F. tularensis LPS conjugated to  Alexa Fluor 647 after digitonin 
permeabilization of the cytoplasmic membrane (region R10). Vacuolar bacteria were 
inaccessible to antibody, and therefore GFP positive only (region R9). Representative flow 
cytometry data of bacteria recovered (A) 10 minutes or (B) 60 minutes post-inoculation. The 
value shown in region R10 represents the percent of intracellular bacteria that are 
cytoplasmic. (C) Percent of intracellular bacteria present in the cytoplasm at designated times 
post-inoculation 
 
 
  
BA
0
10
20
30
40
50
60
70
80
90
100
10 min 20 min 30 min 60 min 2hr
%
 C
yt
o
p
la
sm
ic
% Cytoplasmic
C
18.9% 30.4%
100 
 
References 
1. Anthony, L. D., R. D. Burke, and F. E. Nano. 1991. Growth of Francisella spp. in 
rodent macrophages. Infect Immun 59:3291-6. 
2. Armstrong, L., A. R. Medford, K. M. Uppington, J. Robertson, I. R. Witherden, 
T. D. Tetley, and A. B. Millar. 2004. Expression of functional toll-like receptor-2 
and -4 on alveolar epithelial cells. Am J Respir Cell Mol Biol 31:241-5. 
3. Balagopal, A., A. S. MacFarlane, N. Mohapatra, S. Soni, J. S. Gunn, and L. S. 
Schlesinger. 2006. Characterization of the receptor-ligand pathways important for 
entry and survival of Francisella tularensis in human macrophages. Infect Immun 
74:5114-25. 
4. Biswas, D., K. Itoh, and C. Sasakawa. 2003. Role of microfilaments and 
microtubules in the invasion of INT-407 cells by Campylobacter jejuni. Microbiol 
Immunol 47:469-73. 
5. Bolger, C. E., C. A. Forestal, J. K. Italo, J. L. Benach, and M. B. Furie. 2005. The 
live vaccine strain of Francisella tularensis replicates in human and murine 
macrophages but induces only the human cells to secrete proinflammatory cytokines. 
J Leukoc Biol 77:893-7. 
6. Bosio, C. M., and S. W. Dow. 2005. Francisella tularensis induces aberrant 
activation of pulmonary dendritic cells. J Immunol 175:6792-801. 
7. Checroun, C., T. D. Wehrly, E. R. Fischer, S. F. Hayes, and J. Celli. 2006. 
Autophagy-mediated reentry of Francisella tularensis into the endocytic 
compartment after cytoplasmic replication. Proc Natl Acad Sci U S A 103:14578-83. 
8. Clemens, D. L., B. Y. Lee, and M. A. Horwitz. 2004. Virulent and avirulent strains 
of Francisella tularensis prevent acidification and maturation of their phagosomes 
and escape into the cytoplasm in human macrophages. Infect Immun 72:3204-17. 
9. Cole, L. E., K. A. Shirey, E. Barry, A. Santiago, P. Rallabhandi, K. L. Elkins, A. 
C. Puche, S. M. Michalek, and S. N. Vogel. 2007. Toll-like receptor 2-mediated 
signaling requirements for Francisella tularensis live vaccine strain infection of 
murine macrophages. Infect Immun 75:4127-37. 
10. Cossart, P., and P. J. Sansonetti. 2004. Bacterial invasion: the paradigms of 
enteroinvasive pathogens. Science 304:242-8. 
11. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. 
Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, S. R. Lillibridge, J. 
101 
 
E. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, 
and K. Tonat. 2001. Tularemia as a biological weapon: medical and public health 
management. Jama 285:2763-73. 
12. Dramsi, S., and P. Cossart. 1998. Intracellular pathogens and the actin cytoskeleton. 
Annu Rev Cell Dev Biol 14:137-66. 
13. Feldman, K. A., R. E. Enscore, S. L. Lathrop, B. T. Matyas, M. McGuill, M. E. 
Schriefer, D. Stiles-Enos, D. T. Dennis, L. R. Petersen, and E. B. Hayes. 2001. An 
outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med 
345:1601-6. 
14. Fields, P. I., R. V. Swanson, C. G. Haidaris, and F. Heffron. 1986. Mutants of 
Salmonella typhimurium that cannot survive within the macrophage are avirulent. 
Proc Natl Acad Sci U S A 83:5189-93. 
15. Finlay, B. B., and P. Cossart. 1997. Exploitation of mammalian host cell functions 
by bacterial pathogens. Science 276:718-25. 
16. Finlay, B. B., and S. Falkow. 1997. Common themes in microbial pathogenicity 
revisited. Microbiol Mol Biol Rev 61:136-69. 
17. Forslund, A. L., K. Kuoppa, K. Svensson, E. Salomonsson, A. Johansson, M. 
Bystrom, P. C. Oyston, S. L. Michell, R. W. Titball, L. Noppa, E. Frithz-
Lindsten, M. Forsman, and A. Forsberg. 2006. Direct repeat-mediated deletion of a 
type IV pilin gene results in major virulence attenuation of Francisella tularensis. 
Mol Microbiol 59:1818-30. 
18. Gentry, M., J. Taormina, R. B. Pyles, L. Yeager, M. Kirtley, V. L. Popov, G. 
Klimpel, and T. Eaves-Pyles. 2007. Role of primary human alveolar epithelial cells 
in host defense against Francisella tularensis infection. Infect Immun 75:3969-78. 
19. Golovliov, I., V. Baranov, Z. Krocova, H. Kovarova, and A. Sjostedt. 2003. An 
attenuated strain of the facultative intracellular bacterium Francisella tularensis can 
escape the phagosome of monocytic cells. Infect Immun 71:5940-50. 
20. Golovliov, I., A. Sjostedt, A. Mokrievich, and V. Pavlov. 2003. A method for 
allelic replacement in Francisella tularensis. FEMS Microbiol Lett 222:273-80. 
21. Hall, J. D., R. R. Craven, J. R. Fuller, R. J. Pickles, and T. H. Kawula. 2006. 
Francisella tularensis Replicates Within Alveolar Type II Epithelial Cells in vitro 
and in vivo Following Inhalation. Infect Immun. 
102 
 
22. Heithoff, D. M., R. L. Sinsheimer, D. A. Low, and M. J. Mahan. 1999. An 
essential role for DNA adenine methylation in bacterial virulence. Science 284:967-
70. 
23. Hong, K. J., J. R. Wickstrum, H. W. Yeh, and M. J. Parmely. 2007. Toll-like 
receptor 2 controls the gamma interferon response to Francisella tularensis by mouse 
liver lymphocytes. Infect Immun 75:5338-45. 
24. Hume, D. A., I. L. Ross, S. R. Himes, R. T. Sasmono, C. A. Wells, and T. Ravasi. 
2002. The mononuclear phagocyte system revisited. J Leukoc Biol 72:621-7. 
25. Ireton, K., B. Payrastre, H. Chap, W. Ogawa, H. Sakaue, M. Kasuga, and P. 
Cossart. 1996. A role for phosphoinositide 3-kinase in bacterial invasion. Science 
274:780-2. 
26. Khan, A. S., S. Morse, and S. Lillibridge. 2000. Public-health preparedness for 
biological terrorism in the USA. Lancet 356:1179-82. 
27. Lauriano, C. M., J. R. Barker, S. S. Yoon, F. E. Nano, B. P. Arulanandam, D. J. 
Hassett, and K. E. Klose. 2004. MglA regulates transcription of virulence factors 
necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc 
Natl Acad Sci U S A 101:4246-9. 
28. Lindemann, S. R., M. K. McLendon, M. A. Apicella, and B. D. Jones. 2007. An in 
vitro model system used to study adherence and invasion of Francisella tularensis 
live vaccine strain in nonphagocytic cells. Infect Immun 75:3178-82. 
29. Mason, R. J. 2006. Biology of alveolar type II cells. Respirology 11 Suppl:S12-5. 
30. Meibom, K. L., I. Dubail, M. Dupuis, M. Barel, J. Lenco, J. Stulik, I. Golovliov, 
A. Sjostedt, and A. Charbit. 2008. The heat-shock protein ClpB of Francisella 
tularensis is involved in stress tolerance and is required for multiplication in target 
organs of infected mice. Mol Microbiol 67:1384-401. 
31. Melillo, A., D. D. Sledjeski, S. Lipski, R. M. Wooten, V. Basrur, and E. R. 
Lafontaine. 2006. Identification of a Francisella tularensis LVS outer membrane 
protein that confers adherence to A549 human lung cells. FEMS Microbiol Lett 
263:102-8. 
32. Nano, F. E., N. Zhang, S. C. Cowley, K. E. Klose, K. K. Cheung, M. J. Roberts, 
J. S. Ludu, G. W. Letendre, A. I. Meierovics, G. Stephens, and K. L. Elkins. 
2004. A Francisella tularensis pathogenicity island required for intramacrophage 
growth. J Bacteriol 186:6430-6. 
103 
 
33. Nutter, J. E., and Q. N. Myrvik. 1966. In vitro interactions between rabbit alveolar 
macrophages and Pasteurella tularensis. J Bacteriol 92:645-51. 
34. Oelschlaeger, T. A., P. Guerry, and D. J. Kopecko. 1993. Unusual microtubule-
dependent endocytosis mechanisms triggered by Campylobacter jejuni and 
Citrobacter freundii. Proc Natl Acad Sci U S A 90:6884-8. 
35. Oyston, P. C., A. Sjostedt, and R. W. Titball. 2004. Tularaemia: bioterrorism 
defence renews interest in Francisella tularensis. Nat Rev Microbiol 2:967-78. 
36. Patel, J. C., and J. E. Galan. 2005. Manipulation of the host actin cytoskeleton by 
Salmonella--all in the name of entry. Curr Opin Microbiol 8:10-5. 
37. Pechous, R., J. Celli, R. Penoske, S. F. Hayes, D. W. Frank, and T. C. Zahrt. 
2006. Construction and characterization of an attenuated purine auxotroph in a 
Francisella tularensis live vaccine strain. Infect Immun 74:4452-61. 
38. Pierini, L. M. 2006. Uptake of serum-opsonized Francisella tularensis by 
macrophages can be mediated by class A scavenger receptors. Cell Microbiol 8:1361-
70. 
39. Pizarro-Cerda, J., and P. Cossart. 2006. Subversion of cellular functions by 
Listeria monocytogenes. J Pathol 208:215-23. 
40. Pizarro-Cerda, J., and P. Cossart. 2004. Subversion of phosphoinositide 
metabolism by intracellular bacterial pathogens. Nat Cell Biol 6:1026-33. 
41. Qin, A., and B. J. Mann. 2006. Identification of transposon insertion mutants of 
Francisella tularensis tularensis strain Schu S4 deficient in intracellular replication in 
the hepatic cell line HepG2. BMC Microbiol 6:69. 
42. Raynaud, C., K. L. Meibom, M. A. Lety, I. Dubail, T. Candela, E. Frapy, and A. 
Charbit. 2007. Role of the wbt locus of Francisella tularensis in lipopolysaccharide 
O-antigen biogenesis and pathogenicity. Infect Immun 75:536-41. 
43. Richardson, W. P., and J. C. Sadoff. 1988. Induced engulfment of Neisseria 
gonorrhoeae by tissue culture cells. Infect Immun 56:2512-4. 
44. Rosenberger, C. M., and B. B. Finlay. 2003. Phagocyte sabotage: disruption of 
macrophage signalling by bacterial pathogens. Nat Rev Mol Cell Biol 4:385-96. 
45. Rosenshine, I., V. Duronio, and B. B. Finlay. 1992. Tyrosine protein kinase 
inhibitors block invasin-promoted bacterial uptake by epithelial cells. Infect Immun 
60:2211-7. 
104 
 
46. Santic, M., M. Molmeret, and Y. Abu Kwaik. 2005. Modulation of biogenesis of 
the Francisella tularensis subsp. novicida-containing phagosome in quiescent human 
macrophages and its maturation into a phagolysosome upon activation by IFN-
gamma. Cell Microbiol 7:957-67. 
47. Schulert, G. S., and L. A. Allen. 2006. Differential infection of mononuclear 
phagocytes by Francisella tularensis: role of the macrophage mannose receptor. J 
Leukoc Biol 80:563-71. 
48. Staples, J. E., K. A. Kubota, L. G. Chalcraft, P. S. Mead, and J. M. Petersen. 
2006. Epidemiologic and molecular analysis of human tularemia, United States, 
1964-2004. Emerg Infect Dis 12:1113-8. 
49. Steele-Mortimer, O., J. H. Brumell, L. A. Knodler, S. Meresse, A. Lopez, and B. 
B. Finlay. 2002. The invasion-associated type III secretion system of Salmonella 
enterica serovar Typhimurium is necessary for intracellular proliferation and vacuole 
biogenesis in epithelial cells. Cell Microbiol 4:43-54. 
50. Stone, K. C., R. R. Mercer, P. Gehr, B. Stockstill, and J. D. Crapo. 1992. 
Allometric relationships of cell numbers and size in the mammalian lung. Am J 
Respir Cell Mol Biol 6:235-43. 
51. Takenawa, T., and T. Itoh. 2001. Phosphoinositides, key molecules for regulation of 
actin cytoskeletal organization and membrane traffic from the plasma membrane. 
Biochim Biophys Acta 1533:190-206. 
52. Tarnvik, A., H. S. Priebe, and R. Grunow. 2004. Tularaemia in Europe: an 
epidemiological overview. Scand J Infect Dis 36:350-5. 
53. Teis, D., and L. A. Huber. 2003. The odd couple: signal transduction and 
endocytosis. Cell Mol Life Sci 60:2020-33. 
54. Thakran, S., H. Li, C. L. Lavine, M. A. Miller, J. E. Bina, X. R. Bina, and F. Re. 
2008. Identification of Francisella tularensis Lipoproteins That Stimulate the Toll-
like Receptor (TLR) 2/TLR1 Heterodimer. J Biol Chem 283:3751-60. 
55. Valiron, O., N. Caudron, and D. Job. 2001. Microtubule dynamics. Cell Mol Life 
Sci 58:2069-84. 
 
CHAPTER 5 
 RipA, a Cytoplasmic Membrane Protein Unique to Francisella Species is Required for 
Intracellular Survival 
 
James R. Fuller, Robin R. Craven, Joshua D. Hall, Todd M. Kijek,  
Sharon Taft-Benz, and Thomas H. Kawula 
 
Department of Microbiology and Immunology, School of Medicine  
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 
 
Abstract 
Francisella tularensis is a highly virulent facultative intracellular pathogen that is the 
etiologic agent of the zoonotic disease tularemia. An F. tularensis LVS strain with a 
transposon insertion into FTL1914 invaded, but failed to replicate in tested epithelial cell 
lines. This strain did, however, replicate within macrophages, albeit to a lesser extent than the 
parental strain. A deletion strain lacking FTL1914 was constructed. This strain did not 
replicate in either epithelial or macrophage–like cells, and intracellular replication was 
restored by the wild type allele in trans. Based on the deletion mutant phenotype FTL1914 
was termed ripA (Required for Intracellular Persistence, Factor A). Following uptake by 
J774.A1 cells, F. tularensis ΔripA escaped from the phagosome at the same rate and 
frequency as wild type F. tularensis LVS. In a mouse model of pulmonary tularemia, F. 
tularensis ΔripA was significantly impaired in its ability to persist in the lung and in its 
capacity to disseminate and colonize the liver and spleen.  Molecular characterization of ripA 
revealed that it is expressed by an independent promoter as a single transcript.  The RipA 
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protein is expressed during growth in laboratory media, and localizes to the cytoplasmic 
membrane.  RipA is a novel factor that is necessary for F. tularensis intracellular survival 
and virulence.    
 
Introduction 
Francisella tularensis is a highly virulent zoonotic pathogen that is the etiologic agent 
of the disease tularemia. Francisella has been isolated from over 250 animal species 
including mice, rabbits, and squirrels (5).  Transmission to humans occurs through infected 
arthropod bites (47), physical contact with infected animal tissues (10), contaminated water 
(9, 58), or inhalation of aerosolized organisms (20).  Transmission by inhalation results in the 
most aggressive form of tularemia with as few as 10 colony forming units (CFU) leading to a 
disease (64) that can rapidly progress (72) resulting in mortality rates as high as 60% if left 
untreated (18).  Individual cases of tularemia occur throughout the Northern hemisphere (41) 
with clusters of outbreaks occurring in Scandinavia (73), Europe (31, 39), and the American 
Midwest (66).  Reported cases of tularemia peaked in the United States during the 1930’s and 
1940’s, but have since declined with only 1368 cases between 1990 and 2000 (11).  Because 
of its high virulence and relative ease of propagation, research into the weaponization of F. 
tularensis was conducted by Japan during World War II, and by the United States and Soviet 
Union during the Cold War era (18).  The Department of Health and Human Services (HHS) 
and the United States Department of Agriculture (USDA) recently categorized F. tularensis 
as a select agent based on the potential risk to public health resulting in a revitalized interest 
in F. tularensis. 
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F. tularensis is subdivided into Type A and Type B.  Type A is characterized by high 
virulence and geographic localization to North America; although recently Type A was 
isolated in Europe as well (32).  Type B is distributed throughout the Northern Hemisphere 
and has a lower associated mortality than Type A. Type B F. tularensis was used to create an 
attenuated live vaccine strain (LVS) for use in the Soviet Union (69); however, this vaccine 
is not licensed for use in the United States.  F. tularensis LVS is attenuated in humans, but 
pathogenic in mouse and cell culture models making it an excellent model for the study of 
Francisella pathogenesis (22). 
F. tularensis is a facultative intracellular pathogen.  The ability to replicate in various 
cell types such as alveolar macrophages (3, 53, 56, 68), dendritic cells (8), and lung alveolar 
Type II epithelial cells (23, 34) are all considered to be important in the pathogenesis of 
Francisella. Virulence factors such as mglA (4), iglA (17), iglC (44, 45, 63), tolC (25), clpB 
(48), Type IV pili (21, 24, 33), and a recently identified 58 kDa protein (70) have all been 
characterized using macrophage and mouse models of infection.  Yet the actual function of 
many of these proteins remains to be determined.  We screened a transposon insertion library 
to identify additional genes that contribute to the intracellular growth of F. tularensis. Herein 
we describe one such gene that is required for intracellular growth and virulence in a mouse 
model of tularemia. 
 
Materials and Methods 
Bacterial strains and Cell culture   
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Francisella tularensis Live Vaccine Strain (LVS) was obtained from the Centers for 
Disease Control and Prevention, Atlanta, Ga. F. tularensis LVS was propagated on chocolate 
agar (25g/l BHI, 50µg/ml hemoglobin, 15g/l agarose) supplemented with 1% IsoVitaleX 
(Becton-Dickson), complete BHI broth (35g/l BHI, 50µg/ml hemin, 1% IsoVitalex), or 
Chamberlains Defined Media (12).  All bacterial strains cultured on chocolate agar were 
grown at 37°C.  Broth cultures were incubated in a shaking water bath at 37 ºC. 
TC-1 (ATCC CRL-2785) is a tumor cell line derived from primary lung epithelial 
cells of C57BL/6 mice.  J774A.1 (ATCC TIB-67) is a reticulum cell sarcoma mouse 
macrophage-like cell line.  Cell lines were cultured in the ATCC recommended media at 37 
ºC and 5% CO2 atmosphere. 
 
Plasmids and Molecular Techniques 
  Cloning of F. tularensis LVS DNA was conducted by PCR amplification of 
genomic DNA using Pfu turbo DNA polymerase (Stratagene) and cloned into pCR Blunt-II 
TOPO vector (Invitrogen) using the manufacturer’s protocols.  Plasmids for 
complementation experiments were created by ligating cloned regions of the F. tularensis 
LVS genome into pKK MCS, a pKK214 GFP (1) derivative where a gfp tet
R
 fragment was 
removed and replaced with a fragment containing a multiple cloning site (MCS) and a kan
R
 
allele.  The kanamycin resistance gene was a F. tularensis codon optimized version of aphA1 
synthesized by Blue Heron Biotechnology that is expressed from a modified F. tularensis 
groEL promoter (19).  
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Gentamycin Protection Assay   
To determine the rate of intracellular invasion and replication, F. tularensis LVS 
strains were cultured to mid-exponential phase in Chamberlains Defined Media and then 
added to J774 or Tc-1 monolayers at a multiplicity of infection (MOI) of 100 in 200µl 
prewarmed tissue culture media.  Gentamycin protection assays were then conducted as 
described previously (34). Assays were done in triplicate and statistical significance was 
determined using unpaired t tests with unequal variance on the log transforms of recovered 
CFU to compare mutant strains to the wild type. 
 
Mutagenesis and Allelic Exchange.   
A ripA deletion construct was made by Splice Overlap Extension (SOE) PCR (40) 
using primers designed to delete the ripA locus and maintain 1kb flanking regions.  All ripA 
sequence between the start to the stop codon was deleted.  The construct was sequenced to 
confirm the deletion was in frame and for the integrity of the flanking DNA sequence.  A 
BamHI-NotI fragment containing the deleted allele was ligated into pMP590 kan
R
sacB for 
allelic exchange (46).  Kanamycin (10µg/ml) was used to select for plasmid integration and 
10% sucrose to counter select for resolution as described by LoVullo et el. (46).  Based on 
sucrose resistance and kanamycin sensitivity strains were screened for the loss of the wild 
type allele and retention of the deletion allele by PCR of genomic DNA. 
 
Invasion and Vacuolar Escape Assay.   
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Intracellular bacteria accessible to cytoplasmically delivered antibodies were 
enumerated by the methods described previously (16).  F. tularensis LVS ΔripA accessibility 
to the cytoplasm was compared to wild type at 20 minutes, 60 minutes, and 180 minutes post 
invasion in J774 cells in triplicate assays per time point.  Bacteria accessible to the cytoplasm 
are described as vacuolar and bacteria inaccessible to the cytoplasm as cytoplasmic. 
 
Mouse Model of Pulmonary Infection.   
Francisella strains were prepared for intranasal inoculation by culturing in 
Chamberlains Defined Media to mid-exponential phase prior to suspension in PBS.  
Anesthetized 6- to 8-week-old female C57BL/6 mice
 
were inoculated intranasally with 10
5
 
CFU of F. tularensis suspended in 50 µl
 
of PBS.  Inoculations were conducted in groups of 
four mice for each time point.  Organ burdens were evaluated by homogenization and serial 
dilution before plating on Chocolate agar to determine recovered CFU per organ as described 
previously (Hall).  To compare mutant strain to wild type organ burdens statistical analysis 
was conducted on log transforms of organ burdens using independent unpaired t-test.  
 
Reverse Transcriptase PCR 
  Total RNA was isolated from mid-exponential phase F. tularensis LVS in 
Chamberlains Defined Media using a mirVana RNA isolation kit (Ambion).  Contaminating 
DNA was removed using RQ1 DNase (Promega) in a 1 hour digestion at 37 °C and first 
strand cDNA generated using SuperScript III Reverse transcriptase (Invitrogen) as per the 
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manufacturer’s protocols with 250ng of Random Primers.  First strand cDNA was buffer 
exchanged using a Qiagen QIAquick PCR purification kit.  cDNA was then quantified using 
a ND-1000 (Nanodrop) spectrophotometer.  PCR analysis for expression of ripA, FTL1913, 
and FTL1912 was conducted using 20ng cDNA per 50µl PCR reaction amplified for 25 
cycles.  As a control for DNA contamination a Reverse transcriptase (RT) reaction was 
conducted without the RT enzyme.  Analysis of expression was conducted by agarose gel 
electrophoresis and ethidium bromide staining. 
 
Agarose Formaldehyde Electrophoresis and Northern Analysis   
Total RNA was harvested from mid-exponential phase F. tularensis LVS grown in 
Chamberlains Defined Media using RNAeasy columns (Qiagen).  Total RNA was prepared 
for analysis by concentration using ethanol/sodium acetate precipitation followed by 
quantitation with a ND-1000 spectrophotometer (Nanodrop).  RNA was separated using 
agarose-formaldehyde (2% agarose, 2.2M Formaldehyde) electrophoresis followed by 
capillary transfer to nitrocellulose as in Rueger et al. (61).    Additional lanes of the 
membrane were cut off and stained with methylene blue to assess rRNA bands for 
degradation and equality of loading.  Digoxigenin labeled RNA probes were generated using 
a Northern Starter Kit (Roche) and the manufacturer’s protocols.  Hybridization, washing, 
and detection were done according to the manufacturer’s (Roche) protocols. 
 
Membrane Fractionation  
112 
 
F. tularensis LVS was cultured to mid-exponential phase in Chamberlains Defined 
Media (12), pelleted by centrifugation, and resuspended in lysis buffer (10mM Tris pH 7.5, 
150mM NaCl).  Lysozyme was added to 0.1mg/ml and the bacterial suspension incubated on 
ice for 30 minutes. A 1:1 cell suspension with 0.1mm silica beads was beaten for 15 minutes 
in a Disruptor Genie (Scientific Industries).  Cell lysates were collected after the beads 
settled and the beads were washed 3 times with lysis buffer.  The cell lysate was clarified by 
centrifugation at 12,000 x g for 4 minutes.  The crude membrane fraction was collected by 
ultracentrifugation at 100,000 x g for 90 minutes, and the supernatants were saved as the 
cytosolic fraction.  The crude membrane fraction was washed one time by re-suspension in 
lysis buffer and ultracentrifugation.  The cytoplasmic membrane fraction was solubilized 
with lysis buffer and 10% sarkosyl (Sigma) added to a 0.2% final concentration.  The outer 
membrane fraction was then pelleted by ultracentrifugation at 100,000 x g for 60 minutes 
(17, 52). 
 
Recombinant RipA and anti-RipA Antiserum Production 
 The F. tularensis LVS ripA gene was cloned and sequenced to confirm the integrity 
of the DNA sequence.  The ripA allele was ligated into a pQE30 (Qiagen) vector to construct 
an N terminal 6x His tag fusion.  The ripA::6His allele was induced using 0.1mM IPTG for 4 
hours and harvested by centrifugation.  The cell pellet was lysed by lysozyme treatment and 
sonication, before clarification by centrifugation. The crude membrane fraction was pelleted 
by ultracentrifugation at 115,000 x g for 60 minutes.  RipA::6His was purified from the crude 
membrane fraction using a Qiagen native purification protocol with buffers containing 1% 
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Triton X-100 and 10mM β mercaptoethanol.  The purified RipA::6His was analyzed for 
purity by SDS-PAGE and Coomassie staining.  The purified protein was methanol 
chloroform precipitated (71) and resuspended in PBS.  Purified RipA::6His was sent to 
Proteintech Group, Inc for the production of Rabbit antiserum by the standard Proteintech 
long protocol.  Preimmune bleeds were collected from each rabbit used in the protocol.  
Antiserum was screened for reactivity and specificity by Western blotting of the purified 
protein. 
 
SDS-PAGE and Western Analysis   
SDS-PAGE was conducted by the methods of Laemmli et al (43) utilizing a 
denaturing discontinuous 12.5% acrylamide gel.  Total protein loaded in each sample was 
equivalent as determined by a BCA assay (Pierce).  Proteins were transferred to 
nitrocellulose and blocked in 1% BSA blocking buffer (0.05% Tween 20, PBS) overnight.  
Antibody incubations were conducted in blocking buffer. Membranes were washed in 0.05% 
Tween 20 PBS.  Primary incubations and secondary antibody incubations were for 60 
minutes.  Rabbit anti-RipA serum was used at 1:1000, Chicken anti-AtpB IgY at 1:5000 
(AgriSera), Mouse anti-GFP IgG (Abcam) at 1:1000, Goat anti-rabbit IgG-HRP at 1:10,000 
(Sigma), and Goat anti-Chicken IgG HRP at 1:10,000 (Sigma).  Development was conducted 
using Pierce SuperSignal Pico substrate as the manufacturer’s protocols and exposed to 
autoradiography film. 
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Results 
Identification of RipA as a Virulence Factor 
 To identify genes involved in Francisella virulence, we created and screened a 
transposon mutant library of F. tularensis Live Vaccine Strain (LVS).  Library construction 
was done as described previously (42).  Gentamycin protection assays were conducted in the 
TC-1 lung epithelial cell line to identify strains defective for intracellular growth (Figure 1). 
One mutant strain was identified that invaded epithelial cells at the same frequency as F. 
tularensis LVS, but did not replicate after invasion.  At 6 hours post inoculation there was no 
significant difference between the numbers of intracellular mutant or wild type CFU 
recovered from TC-1 cells; however, by 24 hours post inoculation significantly fewer mutant 
organisms, 1.9x10
5
 versus 1.1x10
7
 CFU (P < 0.001) were recovered from the LVS and Tn5 
mutant infected cells, respectively.   
Identical assays were performed using the J774A.1 mouse macrophage-like cell line 
to compare the intracellular growth of wild type LVS and the Tn5 mutant strain in epithelial 
and macrophage – like cell lines (Figure 5.1).  As in the TC-1 epithelial cell line, the mutant 
and wild type strains entered J774 cells at the same frequency.  However, in contrast to TC-1 
cells, the Tn5 mutant replicated within J774 cells, but to a lesser extent than wild type LVS. 
At 24 hours post inoculation, 8.2x10
7
 versus 8.7x10
6 
CFU (P < 0.01) were recovered from 
LVS and Tn5 mutant infected cells, respectively.  The notable difference when TC-1 and 
J774A.1 cell lines were compared was the amount of intracellular replication of the Tn5 
mutant strain.  No significant replication was observed in TC-1 cells, while moderate 
replication was seen in J774 cells.  These findings were also observed in other lung epithelial 
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cell lines (MLE-12, A549) and in bone marrow derived mouse macrophages (data not 
shown). 
Sequence analysis of the DNA flanking the Tn5 insertion showed that the interrupted 
allele was FTL1914 (Figure 2).  This allele was termed ripA (required for intracellular 
persistence, factor A).  The ripA locus is predicted to encode a 178 amino acid membrane 
protein conserved in all sequenced Francisella strains.  There is only one copy of the locus in 
each sequenced genome.  pBLAST (26) was used to identify similar non-F. tularensis 
proteins (E < 1).  These were hypothetical membrane proteins of unknown function in 
Streptomyces coelicolor A3(2) (E = 1x10
-10
), Beggiatoa sp. PS (E = 2x10
-10
), Moritella sp. 
PE36 (E = 1x10
-9
), Sulfitobacter sp. NAS-14.1 (E = 0.006), Clostridium perfringens C strain 
JGS1495 (E = 0.044), a predicted membrane protein linked to a retron element in 
Escherichia coli (E = 0.36), and a nitric oxide reductase (NorW) in Aeromonas salmonicida 
(E = 0.60).  NorW plays a role in nitric oxide detoxification through interactions with NorR 
and NorV; however, there are no NorR and NorV homologs encoded in the Francisella 
genome and the amino acid similarity is not with the functional oxidoreductase domain of 
NorW.  All the other homologous proteins revealed by the pBLAST analysis were of 
unknown function. 
 
ripA is Required for Intracellular Survival 
 A F. tularensis LVS ripA deletion strain, LVS ΔripA, lacking all but the start and 
stop codons, was created via allelic exchange (29, 46) using a deletion construct generated by 
splice overlap extension (SOE) PCR (Figure 5.2).  Allelic exchange was achieved using the 
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pMP590 vector as described by LuVullo et al. (46).  The doubling time of the resulting 
mutant strain in Chamberlains Defined Media was approximately 150 minutes.  This was not 
significantly different than the growth rate of the wild type LVS seeded in parallel cultures.   
The maximum density of the mutant strain was equivalent to wild type after 24 hours of 
growth in Chamberlains Defined Media (data not shown). 
To assess the effect of deleting ripA on intracellular growth, gentamycin protection 
assays were conducted using the J774A.1 mouse macrophage-like and TC-1 lung epithelial 
cell lines as described previously (34).  Invasion frequencies of the deletion mutant were not 
significantly different from wild type (P values>0.4) in all cases (Figure 5.3).  However, the 
CFU recovered had decreased by 24 hours in both cell types indicating that this mutant had 
an intracellular survival defect.  Mean recovery for LVS and LVS ΔripA was 1.23 x 107 
versus 2.60 x 10
2
 CFU (P<0.001), respectively, at 24 hours in TC-1 lung epithelial cells 
(Figure 5.3A).  Mean recovery for LVS and LVS ΔripA was 1.04 x 108 versus 1.07 x 105 
CFU (P<0.001), respectively, at 24 hours in J774 cells (Figure 5.3B).  Intracellular 
replication of LVS ΔripA was restored by trans complementation with ripA (Figure 5.3).  
The intracellular growth defect of LVS ΔripA was not due to increased sensitivity to 
gentamycin (data not shown).   
 
Intracellular Trafficking of F. tularensis ΔripA 
  Following uptake by host cells, F. tularensis escapes the phagosome and replicates 
within the cytoplasm (13, 27).   Most mutant strains studied to date that fail to replicate 
intracellularly do not escape the phagosome (45, 63) with the notable exception of F. 
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novicida ΔiglD (62) and clpB (48). LVS ΔripA intracellular trafficking in J774A.1 cells was 
compared to LVS using a modification of methods described by Checroun et al. (13).  
J774A.1 chilled monolayers were inoculated with GFP-expressing mutant and wild type 
strains at an MOI of 100 and invasion synchronized by rapid warming At 20, 60 and 180 
minutes post inoculation the number of cytoplasmic versus vacuolar bacteria was determined 
by antibody accessibility following differential membrane permeablization with digitonin.  
At each time point the percentage of antibody accessible mutant and wild type bacteria were 
statistically identical (Figure 5.4).  Thus, the LVS ΔripA strain escaped the phagosome at the 
same rate as wild type LVS.  Further, the intracellular growth defect of this mutant strain is 
not because of a failure to reach the cytoplasm. 
 
RipA is Required for Virulence in a Mouse Model of Infection 
  A mouse model of pulmonary tularemia was used to assess the role of ripA in F. 
tularensis pathogenesis.  Anesthetized C57BL/6 mice were intranasally inoculated with 10
5
 
CFU.  Organ burdens were measured by organ homogenization, serial dilution, and plating to 
determine viable CFU.  Lung burdens were determined two hours post inoculation to monitor 
the delivery of each strain to the lung.  Lung, liver, and spleen organ burdens were 
determined 1, 3, 7, and 14 days post inoculation (Figure 5.5). 
 The CFU recovered from the lungs at 2 hours post inoculation were 2.48 x 10
4
, 1.18 x 
10
4
, and 1.12 x 10
4
 for LVS, LVS ΔripA, and LVS ΔripA pJRF146, respectively (Figure 
5.5A).  An independent two tailed t-test with unequal variance was used to compare the data 
at 2 hours post inoculation (log transforms of the data used to compare later time points).  
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The differences in lung burdens at 2 hours were not statistically different, (P > 0.2) thus the 
strains were delivered to the lung at equivalent frequencies.  However, by day 1, the organ 
burdens of LVS ΔripA infected animals were significantly lower than those of wild type and 
complemented mutant strains (P<0.001).  The number of LVS ΔripA organisms in the lung 
decreased in the first 24 hours, during the same time period, the number of both wild type 
and complemented strains increased by at least one order of magnitude. LVS ΔripA was not 
detected in the liver or spleen before day seven. Recovery of this strain was particularly low 
with only 1 mouse (day 7) out of 16 mice having a detectable spleen burden (> 30 CFU).  By 
day 7 post inoculation, significant pathology was noted in mice infected with either LVS or 
LVS ΔripA pJRF146 ripA  (enlarged spleens 4 out of 4, liver lesions 1 out of 4.)  Mice 
infected with wild type LVS were euthanized at day 7 due to significant mouse morbidity, 
reflecting the lack of day 14 data for the wild type organ burdens. Organ burdens were 
reduced by day 14 in mice infected with LVS ΔripA or LVS ΔripA pJRF146 ripA relative to 
day 7 (P<0.01); however, one mouse infected with the complemented mutant strain died on 
day 8.    These data indicate that deletion of ripA results in significant attenuation of LVS. 
   
The ripA gene is independently transcribed   
Analysis of the ripA locus using FGENESB (www.softberry.com) suggested that ripA 
may be co-transcribed with FTL1913.  A combination of reverse transcriptase (RT) PCR and 
Northern analysis was used to address this possibility.  RT-PCR utilizing primer sets in ripA, 
FTL1913, and FTL1912 were used to map transcripts (Figure 5.6A).  FTL1912 was included 
because there is a predicted Rho independent terminator between FTL1912 and FTL1913. 
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The presence of bridging transcripts was assessed by RT-PCR using primers in adjacent 
reading frames (Figure 5.6A). 
FTL1912, FTL1913 and ripA were all expressed under the conditions tested. There 
was a lack of any detectible product from reaction utilizing primers bridging FTL1912 and 
FTL1913 suggesting that the predicted Rho independent terminator prevented transcription 
bridging the reading frames (Figure 5.6B).  A faint amplification product was present in 
reactions using FTL1913 – ripA bridging primers.  However, the band intensity was 
significantly lower than that of gene specific products (Figure 6B) suggesting that 
transcriptional termination occurred 3’ of FTL1913 and that ripA was predominantly 
contained in an independent transcript. 
Northern analysis of total RNA harvested from mid exponential phase LVS and LVS 
ripA::tn5 was used to measure the size of the ripA containing transcript.  In vitro 
transcription was used to incorporate digoxigenin into a 500 nucleotide RNA probe specific 
to the 3’ end of ripA.  A 600 nucleotide ripA RNA was present in the wild type strain based 
on a digoxigenin labeled RNA ladder (Figure 5.6C), which is consistent with the 537 
nucleotide ripA gene being transcribed independently.  No ripA message was detected in The 
LVS  ripA::tn5 RNA samples. 
 
Characterization of RipA   
Subcellular fractions of LVS, LVS ΔripA, LVS ΔripA pJRF146 ripA, and LVS 
ripA::tn5 were analyzed by Western blotting using anti-RipA antiserum (Figure 5.7A).  RipA 
migrated at a relative molecular weight of 17 kDa. RipA protein was not detected in LVS 
120 
 
ΔripA or LVS ripA::tn5.  Complementation with the native ripA allele in a multicopy plamid 
led to overexpression relative to the wild type strain. 
When the translated amino acid sequence was analyzed with TopPred (14), RipA was 
predicted to be localized to the cytoplasmic membrane with three transmembrane domains 
and the amino terminus in the cytoplasm.  Analysis of LVS pKK214gfp cytosolic, 
cytoplasmic membrane, and outer membrane enriched fractions (17, 52) by Western blot 
revealed that RipA localized to the cytoplasmic membrane fraction (Figure 5.7B).  RipA was 
differentiated from proteins that reacted non-specifically with the RipA anti-serum by 
probing corresponding samples with preimmune serum.  Antibodies to AtpB (Agrisera) and 
Gfp (Abcam) were used to determine subcellular fraction purity. GFP, a soluble cytosolic 
protein was detected with a Mouse anti-GFP monoclonal antibody.  No GFP was detected in 
either membrane fraction.  Low levels of AtpB and RipA were detected in the outer 
membrane fraction, indicating that the outer membrane fraction had low level contamination 
with cytoplasmic membrane proteins.  However, the relative band intensities demonstrate 
that the majority of RipA was present in the cytoplasmic membrane fraction of F. tularensis. 
  
Discussion 
The highly virulent nature of F. tularensis was recognized even before it was isolated 
and identified in the 1920’s as the etiologic agent of a plague like disease in rodents.  It is 
evident that the ability to survive and replicate within diverse host cell types is fundamental 
to F. tularensis pathogenesis.  While the processes of host cell entry, phagosome escape, and 
intracellular replication have been described, the mechanisms used by F. tularensis to 
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achieve these have not.  The recent creation and improvement of tools and procedures for the 
genetic manipulation of F. tularensis has led to the identification of a number of genes that 
are required for intracellular growth and/or virulence in animal models of tularemia. 
 Various F. tularensis mutants including mglA (4), iglA (17, 30), iglC (28, 44, 45) , 
wbtA (15, 65), purF (57), purMCD (55), pmrA (50), clpB (48), acpA (49), and tolC (25) 
exhibit decreased or absent intracellular replication in macrophages and are attenuated in 
mouse models of tularemia.  Phagosomal escape has been studied in five of these mutants.  
F. tularensis clpB and iglD mutants escaped to the cytoplasm (48, 62), while mglA, iglC, and 
acpA mutants failed to escape the phagosome (45, 49, 63).  Little is known about F. 
tularensis mechanisms responsible for phagosome escape or the mechanisms responsible for 
intracellular survival either inside or outside the phagosome. 
Screening of a transposon insertion mutant library resulted in the identification of a 
gene that is required for F. tularensis persistence within host cells.  RipA has homology to 
predicted proteins in other unrelated bacteria, but none of these homologies provide much 
insight into the function of RipA.  We studied the expression and cellular localization of 
RipA in an effort to characterize RipA.  The intracellular trafficking and replication of LVS 
ΔripA was studied as well as its ability to initiate and sustain infection in a mouse model of 
pulmonary tularemia as an indicator of the importance of ripA in Francisella pathogenesis. 
Intracellular pathogens must overcome the host innate immune response to 
successfully colonize the intracellular niche.  The primary host defense is centered on the 
antimicrobial properties of the phagosome.  Most successful intracellular pathogens either 
escape the phagosome or divert phagosome maturation to their own ends.  Francisella 
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quickly escapes the phagosome into the cytoplasmic environment where it replicates (13, 27, 
45).  Recovery of LVS ΔripA within epithelial cells or macrophages decreased dramatically 
after initially invading at the same rate as wild type LVS.  When we evaluated the 
intracellular trafficking of LVS ΔripA, it escaped from the phagosome at the same rate and 
frequency as wild type LVS.  Thus, the intracellular survival defect was not due to failure to 
escape from the phagosome and subsequent killing in the phagolysosome. 
The survival defect of LVS ΔripA is likely due to host innate immunity.  Innate 
immunity in the host cytoplasm can be characterized into compartmentalization by 
autophagy, direct microbiocidal activity, and nutritional deprivation.  Nutritional deprivation 
in the cytoplasm is generally considered to have a bacteriostatic effect (2).  This is 
exemplified by F. tularensis ΔpurF, a purine auxotroph.  F. tularenis ΔpurF fails to replicate 
in the cytoplasm and persists for an extended period before declining gradually (57).   This is 
not the phenotype demonstrated by F. tularensis ΔripA.  It declines dramatically between 6 
hours and 24 hours in the intracellular niche.  Though not conclusive, this rapid loss of 
viability is consistent with the possibility that F. tularensis ΔripA is being degraded 
intracellularly. 
This leaves either sensitivity to direct antimicrobial factors in the cytoplasm or 
autophagy to explain the intracellular killing of F. tularensis ΔripA.  Factors such as 
ubiquicidin (37) and histones have been purified from both the macrophage cytoplasm and 
compartmentalized vesicles and have been shown to have a direct bacteriocidal effect (36, 
38); however, the significance of these factors in pathogenesis is unknown.  Autophagy is 
considered to be an important means by which host cells clear pathogens from the host 
cytoplasm (51, 59).  Most cytoplasmic pathogens studied to date either evade or hijack 
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autophagic mechanisms.  For example, Shigella flexneri and Listeria monocytogenes evade 
autophagy in a process requiring de novo protein synthesis (54, 59).  While Legionella 
pneumophila, Salmonella enterica, and Coxiella burnetti exploit the autophagic machinery 
(6, 7, 35, 60, 67).   Francisella is different in that it escapes to the cytoplasm, and that 
evasion of autophagy, after escape from the vacuole, is not dependent on de novo protein 
synthesis (13).  We hypothesize that autophagy of intracellular F. tularensis ΔripA is the 
most likely mechanism for the decrease in intracellular viability and that the decreased 
intracellular viability is responsible for the severe attenuation in the mouse model of 
infection.            
In an effort to connect RipA with the observed phenotypes of the LVS ΔripA mutant, 
we studied the predicted amino acid sequence to hypothesize a function for RipA.  RipA has 
homology to a group of hypothetical membrane proteins of unknown function in unrelated 
bacterial species.  Homology is limited to conserved domains of RipA suggesting 
conservation of function; however, significant divergence is displayed in other regions of 
RipA.  We propose to investigate the function of RipA through protein-protein interactions 
with the aim of inferring its function based on interacting proteins.  From these interactions a 
function for RipA may be inferred leading to a viable hypothesis on the role of RipA in F. 
tularensis pathogenesis.  
 
Attributions 
I performed the vacuolar escape assays described in this chapter. 
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Figure 5.1.  Gentamycin protection assays of LVS and LVS ripA::tn5 were conducted in 
TC-1 (A) lung epithelial cells or J774A.1 (B) mouse macrophage-like cells at an MOI of 100.  
Mean CFU (N=3) at 6 hours and 24 hours post inoculation with error bars ± one standard 
deviation.  Student’s t-tests were conducted comparing LVS to LVS ripA::tn5 at each time 
point (P<0.01 demarcated by **). 
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Figure 5.2.  (A) Graphical representation of the genomic organization of the LVS ripA locus. 
Loci in close proximity to ripA (FTL 1914) on the chromosome are FTL 1912 (30S 
ribosomal protein S1), FTL 1913 (Sua5/YciO/YrdC family protein), and FTL 1915 
(Acetyltransferase).  Primers utilized for SOE PCR are marked by arrows.  (B)  DNA 
sequence of the ripA deletion marked with the forward and reverse overlapping internal 
primers used in the SOE PCR.  The predicted ribosome binding site (RBS) and the remaining 
ripA codons (M and *) are marked. 
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Figure 5.3.  Gentamycin protection assays were conducted in TC-1 (A) lung epithelial cells 
or J774A.1 (B) mouse macrophage-like cells at an MOI of 100.  Mean CFU (N=3) at 6 hours 
and 24 hours post inoculation with error bars ± one standard deviation.  Student’s t-tests were 
conducted comparing strains to wild type LVS at each time point (P<0.05 emarcated by * 
and P<0.01 demarcated by **).  
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Figure 5.4.  Mean percentage (N=3) of intracellular bacteria in the cytoplasm or vacuole at 
20 minutes, 1 hour, and 3 hours post invasion of J774A.1 mouse macrophage-like cells with 
error bars representing one standard deviation.  Bacteria in the cytoplasm determined by 
accessibility to cytoplasmically delivered antibodies.  Vacuolar bacteria defined as bacteria 
protected from cytoplasmically delivered antibodies. 
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Figure 5.5. Bacterial organ burdens in infected mice (N=4) after intranasal inoculation 
quantitated as CFU and graphed as individual data points.  Organ burdens in mice inoculated 
with LVS vector only (●), LVS ΔripA vector only (○), and LVS ΔripA pJRF146 ripA (▼) 
strains.  Lung (A), liver (B), and spleen (C) burdens were determined at 2 hours (lung only), 
1 day, 3 days, 7 days, and 14 days (LVS ΔripA vector only and   LVS ΔripA pJRF146 ripA) 
post inoculation.  Burdens that were below the limit of detection (~30 CFU) are plotted on 
the X axis. 
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Figure 5.6.  (A) Graphical representation of the ripA region. Primers utilized for RT-PCR 
marked are marked with arrows while the region complementary to the RNA probe used in 
the Northern analysis is demarcated by a solid line.  (B)  RT-PCR analysis of the expression 
of genes FTL1912 (F14-R14), FTL1913 (F13-R13), and ripA (F14-R14) shown in the upper 
image.  Analysis for transcripts bridging FTL1912 to FTL1913 (F12-R13) and FTL1913 to 
ripA (F13-R14) shown in lower image.  PCR of cDNA demarcated by a + and reverse 
transcriptase negative reactions to assess DNA contamination marked as -.  (C) Northern 
analysis to determine the transcript size of ripA containing RNA.  Roche digoxigenin labeled 
RNA ladder is present in the left most lane followed by total RNA from LVS (wt) and LVS 
ripA::tn5.  This analysis used a ripA complementary digoxigenin labeled RNA probe 
demonstrating the presence of monocistonic ripA transcript in LVS and the absence of the 
transcript in LVS ripA::tn5. 
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Figure 5.7.  (A) Western blot analysis of cytoplasmic membrane enriched fractions of LVS, 
LVS ΔripA, LVS ΔripA pJRF146 ripA, and LVS ripA::tn5.  Rabbit anti-RipA (1:1000) 
antiserum was used as the primary antibody.  (B) Subcellular localization of RipA.  Western 
analysis of cytosolic (Cyt.), cytoplasmic membrane (CM), and outer membrane (OM) 
enriched fractions of LVS pKK214 gfp. Non specific bands were determined with 
preimmune serum from the mouse used to generate the mouse anti-RipA serum.  AtpB was 
used as a marker for the cytoplasmic membrane and GFP for the cytoplasm 
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Abstract 
Francisella tularensis is a highly virulent zoonotic bacterial
 
pathogen capable of 
infecting numerous different mammalian species,
 
including humans. Elucidation of the 
pathogenic mechanisms of
 
F. tularensis has been hampered by a lack of tools to genetically
 
manipulate this organism. Herein we describe the use of transposome
 
complexes to create 
insertion mutations in the chromosome of
 
the F. tularensis live vaccine strain (LVS). A Tn5-
derived transposon
 
encoding kanamycin resistance and lacking a transposase gene
 
was 
complexed with transposase enzyme and transformed directly
 
into F. tularensis LVS by 
electroporation. An insertion frequency
 
of 2.6 x 10
–8
 ± 0.87 x 10
–8
 per cell was
 
consistently 
achieved using this method. There are 178 described
 
Tn5 consensus target sites distributed 
throughout the F. tularensis
 
genome. Twenty-two of 26 transposon insertions analyzed were
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within known or predicted open reading frames, but none of these
 
insertions was associated 
with the Tn5 target site. Analysis
 
of the insertions of sequentially passed strains indicated that 
the transposons were maintained stably at the initial insertion
 
site after more than 270 
generations. Therefore, transformation
 
by electroporation of Tn5-based transposon-
transposase complexes
 
provided an efficient mechanism for generating random, stable
 
chromosomal insertion mutations in F. tularensis.
 
 
Francisella tularensis is a gram-negative bacterial pathogen
 
and is the etiologic agent 
of tularemia. The manifestations
 
of tularemia depend on the initial route of inoculation, but
 
all modes of contact can result in sepsis and disseminated disease,
 
with organisms found in 
the liver, spleen, lymph nodes, kidney,
 
and lungs (6, 20, 24, 25). Skin contact results in ulcer 
formation
 
at the site of inoculation, where the organisms multiply and
 
spread to the draining 
lymph nodes. Inhalation of F. tularensis
 
leads to bronchial hemorrhaging, mediastinal 
lymphadenopathy
 
(27), and pneumonia without a corresponding productive cough.
 
Ingestion  
of the organisms can result in oropharyngeal tularemia,
 
where patients typically develop 
exudative ulcerative pharyngitis
 
and pharyngeal lymphadenopathy (1, 4).
 
 
F. tularensis strains are divided into two groups, A and B,
 
which are distinguished by 
acid production from glycerol and
 
by citrulline ureidase activity. The two groups of 
organisms
 
exhibit similar pathogenesis; however, group A strains are considered
 
to be highly 
virulent for humans and other animals, whereas
 
group B strains typically cause milder 
disease (28). A live
 
attenuated vaccine strain (LVS) derived from a group B F. tularensis
 
strain has been developed and used to vaccinate laboratory workers
 
(7). This vaccine 
provides significant protection against the
 
highly virulent strains initiated by skin contact (21) 
139 
 
and inhalation
 
(13, 22). However, the basis for attenuation of this strain
 
in humans is not 
known, and it has not been licensed for general
 
public use in the United States.
 
 
F. tularensis can survive within macrophages, a feature that
 
is thought to be important 
in the pathogenesis of this organism
 
(5, 12, 17, 26). F. tularensis subsp. novicida, a related 
organism
 
historically referred to as Francisella novicida, also survives
 
within macrophages, 
but it is an animal pathogen that does not
 
infect humans. Two different genetic loci, termed 
mglAB for
 
macrophage growth locus (2) and iglABCD for intracellular growth
 
locus (11), 
have been identified in F. tularensis subsp. novicida
 
that contribute to its survival in 
macrophages. The function
 
of the igl gene products in promoting this survival has not
 
been 
determined. MglA of F. tularensis subsp. novicida has recently
 
been shown to function as a 
positive regulator for at least
 
seven different genes (16) that are normally induced in 
macrophages,
 
including iglC. An F. tularensis subsp. novicida mutant lacking
 
mglA is unable 
to survive in cultured macrophages and is attenuated
 
in mice (16). Homologues of these 
genes are present in both
 
group A and B F. tularensis strains, and they presumably serve
 
similar functions in these organisms.
 
 
Apart from the described macrophage survival phenotype and the
 
identification of a 
limited number of genetic loci that contribute
 
to intracellular survival (11), very little is 
known about the
 
molecular mechanisms that support F. tularensis pathogenesis
 
and 
virulence. The lack of tools for the genetic manipulation
 
of F. tularensis has made it difficult 
to identify and dissect
 
the bacterial products and processes that contribute to this
 
organism's 
extraordinary virulence and pathogenesis. Mechanisms
 
of transformation and allelic 
exchange have only recently been
 
described (3, 8, 15), and most of these procedures have 
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been
 
developed in F. tularensis subsp. novicida. Lauriano et al.
 
(15) recently described the 
use of allelic exchange to generate
 
targeted insertion mutations in F. tularensis LVS. They 
also
 
reported that Tn10- and Tn1721-based transposon insertions were
 
unstable in F. 
tularensis and that bacterial gene-encoded transposase-complementing
 
activity may function 
to promote the movement of these transposons. Herein
 
we describe a procedure that uses a 
Tn5 derivative to create
 
insertion mutations in F. tularensis LVS which, unlike Tn10
 
and 
Tn1721, were stably maintained at the initial insertion
 
site.
 
 
F. tularensis LVS was obtained from the Centers for Disease
 
Control and Prevention, 
Atlanta, Ga., and were propagated at
 
37°C on chocolate medium supplemented with 1% 
IsoVitalex
 
(BBL). Multiple colonies from an overnight culture of LVS grown
 
on chocolate 
agar were picked and swabbed onto fresh plates
 
to achieve confluent growth, and they were 
then incubated for
 
16 h. Cells from one plate of freshly confluent LVS were suspended
 
in 6 
ml of wash buffer, consisting of 0.5 M sucrose and 10%
 
glycerol, and then were centrifuged 
at 16,000 x g for 3 min.
 
The pellet was suspended in wash buffer and centrifuged again
 
for a 
total of four washes. The pellet resulting from the final
 
centrifugation was suspended in wash 
buffer to a total volume
 
of 100 µl.
 
 
A procedure initially described by Goryshin et al. (9) to create
 
mutations in 
Salmonella, Proteus, and Escherichia species was
 
used to produce similar transposon 
insertion mutations in F.
 
tularensis LVS. One microliter of EZ::TN <kan-2> transposome
 
complex (Epicentre) containing 0.1 pmol of transposon and 1
 
U of transposase was added to 
100 µl of the washed cell
 
suspension, consisting of 10
9
 to 10
10
 cells in 0.5 M sucrose
 
and 
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10% glycerol. The contents were then mixed and transferred
 
to a 0.1-cm-gap electroporation 
cuvette.
 
 
The EZ::TN <kan-2> transposome contains a derivative of
 
Tn5 that lacks a 
transposase gene and has the transposase enzyme
 
bound to the inverted repeat ends of the 
transposon. The transposase
 
is stably associated with the transposon but is inactive in
 
the 
absence of Mg
2+
. Magnesium ions present inside the bacterium
 
activate the transposase 
following transformation, facilitating
 
transposition into the Francisella chromosome. Thus, 
transposition
 
is dependent simply upon activation of the enzyme and not the
 
expression of a 
foreign transposase gene.
 
 
The transposome was introduced into F. tularensis LVS by electroporation
 
using a 
Bio-Rad Gene Pulsar set at 2.5 kV, 25 µF, and
 
200 . Immediately following electroporation 
the cells were suspended
 
in 1 ml of brain heart infusion broth (BBL) supplemented with
 
50 
µg of hemin/ml, incubated for 1 h at 37°C, and
 
then plated on chocolate agar containing 10 
µg of kanamycin/ml.
 
 
We consistently achieved an insertion frequency of 2.6 x 10
–8 
± 0.87 x 10
–8
 (Table 
6.1), as determined by the number
 
of antibiotic-resistant colonies divided by the total number
 
of potential recipient organisms. The insertion frequency was
 
not appreciably affected by the 
number of bacteria, nor was
 
it improved by increasing the concentration of transposome 
complexes.
 
Recovering the organisms with cold or prewarmed media following
 
electroporation as described for other organisms (23) also did
 
not alter the frequency with 
which we isolated antibiotic-resistant
 
organisms.
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Ideally a transposon will insert randomly throughout a genome
 
in order to be a useful 
tool for creating insertion mutation
 
libraries. The transposon insertion sites were mapped by 
directly
 
sequencing the transposon-chromosome junctions by using oligonucleotide
 
primers 
that hybridize within the transposon. Primers Kan-2
 
FP-1 
(ACCTACAACAAAGCTCTCATCAACC) and JF119 (GGATCAGATCACGCATCTTC)
 
hybridize 70 and 150 bp, respectively, from the end of the transposon
 
adjacent to the 3' end 
of the Kan resistance gene, and primer
 
KAN RP-1 
(GCAATGTAACATCAGAGATTTTGAG) hybridizes 43 bp from the
 
other end of the 
transposon. Individual kanamycin-resistant
 
colonies were picked and restreaked on selective 
media. Chromosomal
 
DNA was prepared from strains by using the MasterPure DNA 
purification
 
kit according to the manufacturer's instructions (Epicentre).
 
 
The precise transposon-chromosome junction sites were determined
 
in a total of 26 
kanamycin-resistant colonies from each of three
 
different transformations. One microgram of 
chromosomal DNA
 
was mixed with 100 pM primer, and DNA sequence was generated
 
by 
the University of North Carolina Genome Analysis Center.
 
The transposon insertion site was 
determined by aligning the
 
sequence to the F. tularensis LVS strain genome database 
produced
 
by the Biology and Biotechnology Research Program Sequencing
 
Group at 
Lawrence Livermore National Laboratory (http://bbrp.llnl.gov/bbrp/html/microbe.html).
 
 
Tn5, the transposon upon which EZ::TN is based, has a reported
 
insertion bias for the 
sequence A-GNTYWRANC-T (where W is A
 
or T, R is A or G, Y is C or T, and N is any 
base) (10). The
 
F. tularensis 1.8-Mbp LVS genome has 178 of these insertion
 
bias sequences, 
but none of the 26 insertions that we analyzed
 
occurred within one of these sites. Of the 26 
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junction sites
 
sequenced, 21 were within potential open reading frames and
 
1 was in the 
transcription termination sequence of an open reading
 
frame, which is consistent with the 
observation that, apart
 
from the Tn5 insertion bias site, this transposon has a propensity
 
for 
inserting into actively transcribed DNA and regions of high
 
superhelical density (18, 19). 
One insertion, B5, was in a gene
 
encoding the RNA polymerase ß subunit; this is an
 
essential 
gene. The insertion is located 12 bases from the 3'
 
end of the gene. F. tularensis LVS does 
not possess a second
 
copy of this gene; thus, it is likely that the B5 mutant still
 
produces a 
functional RNA polymerase ß subunit. Ironically,
 
one of the insertions (strain A10; Table 6.2 
and Figure 6.1) was within
 
a gene reported to encode a Francisella transposase (14). The
 
insertions did not appear to cluster within a specific chromosomal
 
segment (Figure 6.1). 
Insertions in potential reading frames were examined further
 
by translating the 
sequence and blasting the protein database
 
to tentatively identify the products of interrupted 
genes. The
 
majority, but not all, of these mutations occurred in genes
 
that encoded proteins 
with significant homology to proteins
 
with known functions or conserved hypothetical 
proteins (Table
 
6.2).
 
 
Lauriano et al. reported that insertion mutations created by
 
derivatives of the Tn10 
and Tn1721 transposons in the closely
 
related organism F. tularensis subsp. novicida were 
unstable
 
and subject to movement to other chromosomal locations, possibly
 
through the 
activity of a host-encoded transposase (15). We
 
picked five transposon insertion mutation 
strains representing
 
insertions within and outside of potential reading frames, including
 
the 
strain with the insertion in the reported Francisella transposase
 
gene. These strains were 
passed daily for 10 days on kanamycin-containing
 
media, and chromosomal DNA was 
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prepared from cells on passages
 
0, 5, and 10. Southern blots were performed by digesting 5 
µg
 
of chromosomal DNA with EcoRI, which does not cleave the transposon.
 
Digested DNA 
segments were separated by agarose gel electrophoresis,
 
transferred to nylon, and probed 
with digoxigenin-labeled Tn5
 
probe. The Tn5 probe hybridized to identically sized fragments
 
in each of the DNA samples prepared from different passages
 
of the same insertion strain 
(Fig. 2). Given that a single colony
 
is composed of at least 10
8
 organisms, a single passage 
equates
 
to at least 27 generations of growth. Thus, after 10 passages
 
the analyzed insertions 
were stable for a minimum of 270 generations.
 
 
Electroporation of a Tn5-derived transposon-transposase enzyme
 
complex into F. 
tularensis LVS resulted in the creation of random
 
insertion mutant strains at a frequency that 
is sufficient to
 
generate mutant libraries of this organism. These insertions
 
are genetically 
stable and are apparently unaffected by the
 
activities of any potential chromosomally 
encoded transposases.
 
Thus, this scheme will facilitate the use of genetic approaches
 
to study 
the mechanisms of F. tularensis physiology and pathogenesis.
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Input (CFU) No. of mutants Mutants/CFU 
 
2.8 x 10
10
 344 1.0 x 10
–8
 
4.9 x 10
9
 62 1.2 x 10
–8
 
1.1 x 10
9
 50 4.5 x 10
–8
 
2.6 x 10
9
 207 7.0 x 10
–8
 
5.7 x 10
10
 1,097 1.9 x 10
–8
 
2.3 x 10
10
 550 1.0 x 10
–8
 
1.4 x 10
10
 210 1.5 x 10
–8
 
 
 
TABLE 6.1. Transposon insertion frequencies 
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Strain designation Predicted insertion 
 
A1 Extragenic 
A2 Deacyclase 
A3 Guanosine polyphosphate pyrophosphohydrolases 
A4 Hydrolase of HD superfamily 
A5 Metal-dependent hydrolase 
A6 Extragenic 
A8 Hypothetical protein gi34496297 
A9 Extragenic 
A10 Francisella transposase (14) 
B1 ATPase 
B2 Extragenic 
B4 Eflux pump protein 
B5 RNA polymerase ß subunit 
B6 Transcription terminator 
B7 Predicted membrane protein of unknown function, pfam03956 
B8 Phosphate acetyltransferase 
B9 Adenylosuccinate synthase 
B10 UsoAp of Emericella nidulans 
C1 Pyruvate phosphate dikinase 
C2 Methyltransferase 
C3 Isocitrate dehydrogenase 
C4 Chloride channel protein EriC 
C6 Anthranilate synthase 
C7 Tryptophan synthase alpha chain 
C8 Multidrug resistance protein 
C10 Integral membrane protein 
 
TABLE 6.2. Identified transposon insertion sites 
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Figure 6.1. Graphic representation of the chromosomal positions of the 27 identified 
insertion sites. The insertions assessed for stability and depicted in Fig. 2 are labeled. 
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Figure 6.2. Southern blot of five insertion mutants (A6, A10, B1, B2, B5, and C10) and 
wild-type F. tularensis LVS probed with labeled Tn5. Chromosomal DNA was prepared 
from mutants after 0, 5, and 10 passages, digested with EcoRI, and probed. All insertions 
analyzed in this manner retained the transposon at the initial insertion site. 
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CHAPTER 7 
Discussion 
Discussion 
The research described here was directed toward understanding the interaction of 
Francisella tularensis with the lung. Tularemia is contracted via a number of routes, 
including respiratory, oral, ocular and skin contact (1, 3, 14, 17). We have chosen to focus on 
interaction with the lung for several reasons. Untreated pneumonic and thyphoidal forms of 
tularemia with a type A strain have a mortality rate 30-60%, compared to the 5-15% overall 
fatality rate for untreated tularemia by all routes (6). A very small dose of as few as 10 
organisms is necessary for human infection by the respiratory route (21). These facts, along 
with a history of weaponization by the United States, the USSR and Japan, make F. 
tularensis a biodefense concern (2, 4, 6, 15, 23). Therefore, understanding how Francisella 
causes disease in the lung is relevant to developing vaccines that would protect people in the 
event of an aerosol dispersal of F. tularensis, especially with organisms that may have been 
intentionally modified to be resistant to standard treatments. 
Chapters 2 and 3 describe our investigation of cell types infected in a mouse model of 
inhalational tularemia. The existing pathogenesis literature focuses largely on the ability of F. 
tularensis to replicate in macrophages, and the attenuation of those mutants in mice that are 
unable to replicate in macrophages (10, 11, 18-20, 22, 25). In addition to the expected 
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phagocytic cells of the immune system, we also identify type II alveolar epithelial cells 
(ATII) containing F. tularensis in the mouse lung.  
The alveoli are made up of type I and type II alveolar epithelial cells. Type I cells 
(ATI) are responsible for structure of the alveoli and gas exchange, and make up about 95% 
of the surface area of the alveolar epithelium (16). Type II cells (ATII), which make up about 
5% of the alveolar surface area,  have multiple functions in the lung, including the 
production, secretion and recycling of surfactant, proliferation to produce additional type II 
cells as well as transdifferentiation to produce additional type I cells, maintenance of alveolar 
fluid balance, and production of antimicrobial and anti-inflammatory substances (16). Both 
LVS and the type A strain, Schu S4, modulate cytokine production by ATII cells, stimulating 
immune cell chemotaxis in vitro (9). Due to the close proximity between the blood and 
alveolar epithelial cells required for gas exchange and fluid balance, these cells are ideally 
located to provide a portal through which bacteria could disseminate to distal organs.  
While the predominant cell type infected 24 hours post-inoculation with 10
2
 to 10
3
 
CFU of LVS, Schu S4 or F. novicida U112 are alveolar macrophages, 2.4% to 6.0% of all 
infected cells are ATII cells. It should be noted that alveolar epithelial cells are fixed tissue 
cells, and as such cannot migrate to the site of bacteria, but can only take up bacteria that 
happen to come into contact with them. Given that ATII cells only account for 5% of the 
alveolar surface area, this contact is probably a rather low frequency occurrence. The number 
of infected ATII cells increases approximately one log by day 3 post-inoculation. This could 
indicate cell-to-cell spread of Francisella, or additional extracellular organisms coming into 
contact with and being internalized by ATII cells. 
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Using the mouse lung epithelial cell line TC-1, the mouse ATII cell line MLE12 and 
the human ATII cell line A549 as models we demonstrate that F. tularensis is able to invade 
these non-phagocytic cells and replicate in vitro as well (13). This ability to invade epithelial 
cells is particularly interesting given that the majority of naturally incurring infections are 
skin infections. As early as 1927 Edward Francis demonstrated that F. tularensis replicates in 
the epithelial cells of the wood tick’s digestive tract, and that one of the unique features of 
tularemia was the ability of the organism to invade fixed tissue cells (24). 
Some pathogenic bacteria have evolved strategies to invade cells that are not 
professional phagocytes (5, 7, 8). These strategies fall into two categories, termed trigger and 
zipper mechanisms of entry. The trigger mechanism is characterized by the use a bacterial 
type III secretion system to translocate effector proteins into the host cell.  These bacterial 
proteins are able to manipulate host cell signaling, resulting in rearrangement of the 
cytoskeleton and engulfment of the bacterium. The zipper mechanism is characterized by the 
expression on the bacterial surface of a protein that is able to interact with a naturally 
occurring host cell receptor. This receptor-ligand binding leads to host cell signaling events 
that cause internalization of the receptor-bound bacterium. Chapter 4 describes our 
characterization of the internalization of F. tularensis by lung epithelial cells. We describe 
the necessity of host cell actin and microtubule polymerization, as well as PI3 kinase and 
tyrosine kinase signaling, to epithelial cell uptake of F. tularensis. The uptake of killed 
bacteria, along with the lack of a predicted type III secretion system, point toward a receptor 
mediated “zipper” mechanism of entry of F. tularensis into lung epithelial cells. It should be 
noted that we have observed E. coli taken up by lung epithelial cell lines in similar numbers 
to F. tularensis, but the E. coli do not replicate in these cells. This suggests that the ability to 
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replicate in these cells, rather than a F. tularensis-specific induction of uptake, may be more 
relevant to disease. 
Intracellular pathogens have also evolved strategies to avoid lysosomal degradation. 
Among these strategies are halting maturation of the endocytic vacuole, modification of the 
vacuole, and escape into the cytoplasm (12). F. tularensis that has been phagocytosed by 
macrophages survives intracellularly by escaping the endocytic pathway to replicate in the 
cytoplasm. In Chapter 4 we demonstrate that F. tularensis has a similar intracellular 
trafficking pattern in lung epithelial cells to that seen in macrophages. Intracellular bacteria 
are initially contained in an EEA1 containing vacuole, which rapidly matures into a LAMP-1 
containing vacuole, followed by bacteria no longer being contained within a membrane 
bound vacuole as evidenced by both availability to cytoplasmically delivered antibodies and 
electron microscopy. It remains to be determined what role this initial interaction with the 
endocytic pathway plays in bacterial escape and whether blocking endosomal maturation 
would prevent escape into the cytoplasm and intracellular growth. 
The early pathogenesis work in Francisella was primarily done in F. novicida due to 
the availability of genetic tools for use in this subspecies. However, the differences in disease 
outcome, as well as genetic differences at loci known to play a role in pathogenesis, point 
toward the necessity of studying the human pathogenic subspecies tularensis and holarctica. 
Chapter 6 describes our development of transposon mutagenesis in type B F. tularensis. This 
method allows the creation of mutant libraries that can be screened for phenotypes of 
interest. Chapter 5 describes a transposon insertion mutant in the gene FTL1914 that does not 
replicate in epithelial cell lines, but does replicate (although to a lesser extent that wildtype) 
in macrophage-like cell lines. This mutant is also attenuated in a mouse respiratory model of 
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tularemia, where it does not disseminate from the lungs to the liver and spleen, and does not 
cause death in mice. These findings, along with our discovery that ATII cells are infected in 
the mouse, lead us to further investigate the interaction of F. tularensis with lung epithelial 
cells. The inability to restore replication in epithelial cells by complementation of gene 
FTL1914 lead to the creation of a deletion mutant of this gene. The deletion mutant does not 
replicate in epithelial cells or macrophages, leading to the name RipA (Required for 
Intracellular Persistence, Factor A), and is also attenuated in mice. The RipA mutant is taken 
up by both macrophage-like and lung epithelial cell lines similarly to wildtype LVS, and 
escapes the macrophage phagosome at the same rate and frequency as LVS.  
Taken together this work demonstrates the discovery of ATII cells as a site of 
bacterial replication during respiratory tularemia, and describes the F. tularensis invasion of 
and trafficking within lung epithelial cells. Additionally we describe our contribution to the 
field of F. tularensis pathogenesis through the creation of stable transposon insertion mutants 
in LVS, and the potential to use these mutants to identify genes necessary for intracellular 
survival. 
 
158 
 
References 
1. 2005. Tularemia transmitted by insect bites--Wyoming, 2001-2003. MMWR Morb 
Mortal Wkly Rep 54:170-3. 
2. Alibek, K. 1999. Biohazard. Random House, New York, NY. 
3. Arikan, O. K., C. Koc, and O. Bozdogan. 2003. Tularemia presenting as 
tonsillopharyngitis and cervical lymphadenitis: a case report and review of the 
literature. Eur Arch Otorhinolaryngol 260:298-300. 
4. Christopher, G. W., T. J. Cieslak, J. A. Pavlin, and E. M. Eitzen, Jr. 1997. 
Biological warfare. A historical perspective. Jama 278:412-7. 
5. Cossart, P., and P. J. Sansonetti. 2004. Bacterial invasion: the paradigms of 
enteroinvasive pathogens. Science 304:242-8. 
6. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. 
Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, S. R. Lillibridge, J. 
E. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, 
and K. Tonat. 2001. Tularemia as a biological weapon: medical and public health 
management. Jama 285:2763-73. 
7. Finlay, B. B., and P. Cossart. 1997. Exploitation of mammalian host cell functions 
by bacterial pathogens. Science 276:718-25. 
8. Finlay, B. B., and S. Falkow. 1997. Common themes in microbial pathogenicity 
revisited. Microbiol Mol Biol Rev 61:136-69. 
9. Gentry, M., J. Taormina, R. B. Pyles, L. Yeager, M. Kirtley, V. L. Popov, G. 
Klimpel, and T. Eaves-Pyles. 2007. Role of primary human alveolar epithelial cells 
in host defense against Francisella tularensis infection. Infect Immun 75:3969-78. 
10. Golovliov, I., M. Ericsson, G. Sandstrom, A. Tarnvik, and A. Sjostedt. 1997. 
Identification of proteins of Francisella tularensis induced during growth in 
macrophages and cloning of the gene encoding a prominently induced 23-kilodalton 
protein. Infect Immun 65:2183-9. 
11. Golovliov, I., A. Sjostedt, A. Mokrievich, and V. Pavlov. 2003. A method for 
allelic replacement in Francisella tularensis. FEMS Microbiol Lett 222:273-80. 
12. Hackstadt, T. 2000. Redirection of host vesicle trafficking pathways by intracellular 
parasites. Traffic 1:93-9. 
13. Hall, J. D., R. R. Craven, J. R. Fuller, R. J. Pickles, and T. H. Kawula. 2006. 
Francisella tularensis Replicates Within Alveolar Type II Epithelial Cells in vitro 
and in vivo Following Inhalation. Infect Immun. 
159 
 
14. Halperin, S. A., T. Gast, and P. Ferrieri. 1985. Oculoglandular syndrome caused 
by Francisella tularensis. Clin Pediatr (Phila) 24:520-2. 
15. Harris, S. 1992. Japanese biological warfare research on humans: a case study of 
microbiology and ethics. Ann N Y Acad Sci 666:21-52. 
16. Mason, R. J. 2006. Biology of alveolar type II cells. Respirology 11 Suppl:S12-5. 
17. Matyas, B. T., H. S. Nieder, and S. R. Telford, 3rd. 2007. Pneumonic tularemia on 
Martha's Vineyard: clinical, epidemiologic, and ecological characteristics. Ann N Y 
Acad Sci 1105:351-77. 
18. Meibom, K. L., I. Dubail, M. Dupuis, M. Barel, J. Lenco, J. Stulik, I. Golovliov, 
A. Sjostedt, and A. Charbit. 2008. The heat-shock protein ClpB of Francisella 
tularensis is involved in stress tolerance and is required for multiplication in target 
organs of infected mice. Mol Microbiol 67:1384-401. 
19. Nano, F. E., N. Zhang, S. C. Cowley, K. E. Klose, K. K. Cheung, M. J. Roberts, 
J. S. Ludu, G. W. Letendre, A. I. Meierovics, G. Stephens, and K. L. Elkins. 
2004. A Francisella tularensis pathogenicity island required for intramacrophage 
growth. J Bacteriol 186:6430-6. 
20. Raynaud, C., K. L. Meibom, M. A. Lety, I. Dubail, T. Candela, E. Frapy, and A. 
Charbit. 2007. Role of the wbt locus of Francisella tularensis in lipopolysaccharide 
O-antigen biogenesis and pathogenicity. Infect Immun 75:536-41. 
21. Saslaw, S., H. T. Eigelsbach, J. A. Prior, H. E. Wilson, and S. Carhart. 1961. 
Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 107:702-14. 
22. Sebastian, S., S. T. Dillon, J. G. Lynch, L. T. Blalock, E. Balon, K. T. Lee, L. E. 
Comstock, J. W. Conlan, E. J. Rubin, A. O. Tzianabos, and D. L. Kasper. 2007. 
A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine 
strain has attenuated virulence while retaining its protective capacity. Infect Immun 
75:2591-602. 
23. Shoham, D., and Z. Wolfson. 2004. The Russian biological weapons program: 
vanished or disappeared? Crit Rev Microbiol 30:241-61. 
24. Simpson, W. M. 1929. Tularemia: History, Pathology, Diagnosis and Treatment. 
25. Twine, S., M. Bystrom, W. Chen, M. Forsman, I. Golovliov, A. Johansson, J. 
Kelly, H. Lindgren, K. Svensson, C. Zingmark, W. Conlan, and A. Sjostedt. 
2005. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to 
express a 58-kilodalton protein is attenuated for virulence and is an effective live 
vaccine. Infect Immun 73:8345-52. 
  
 
